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Thoracic Aortic Aneurysms and Dissections (TAAD) are the fifteenth leading cause
of death in the United States. About 15% of TAAD patients have family history of the
disease. The most commonly mutated gene in these families is ACTA2, encoding smooth
muscle-specific α-actin. ACTA2 missense mutations predispose individuals both to TAAD
and to vascular occlusive disease of small, muscular arteries.
Mice carrying an Acta2 R258C mutant transgene with a wildtype Acta2 promoter
were generated and bred with Acta2-/- mice to decrease the wildtype: mutant Acta2 ratio.
Acta2+/+ R258C TG mice have decreased aortic contractility without aortic disease. Acta2+/- R258C
TG

mice, however, have significant aortic dilatations by 12 weeks of age and a

hyperproliferative response to injury. We characterized smooth muscle cells (SMCs) from
both mouse models under the hypothesis that mutant α-actin has a dominant negative effect,
leading to impaired contractile filament formation/stability, improper focal adhesion
maturation and increased proliferation.
Explanted aortic SMCs from Acta2+/+

R258C TG

mice are differentiated - they form

intact filaments, express higher levels of contractile markers compared to wildtype SMCs

vi

and have predominantly nuclear Myocardin-Related Transcription Factor A (MRTF-A)
localization. However, ultracentrifugation assays showed large unpolymerized actin
fractions, suggesting that the filaments are brittle. In contrast, Acta2+/- R258C TG SMCs are less
well-differentiated, with pools of unpolymerized actin, more cytoplasmic MRTF-A and
decreased contractile protein expression compared to wildtype cells. Ultracentrifugation
assays after treating Acta2+/- R258C TG SMCs with phalloidin showed actin filament fractions,
indicating that mutant α-actin can polymerize into filaments.
Both Acta2+/+

R258C TG

and Acta2+/-

R258C TG

SMCs have larger and more peripheral

focal adhesions compared to wildtype SMCs. Rac1 was more activated in Acta2+/+ R258C TG
SMCs; both Rac1 and RhoA were less activated in Acta2+/- R258C TG SMCs, and FAK was
more activated in both transgenic SMC lines compared to wildtype. Proliferation in both cell
lines was significantly increased compared to wildtype cells and could be partially
attenuated by inhibition of FAK or PDGFRβ. These data support a dominant negative effect
of the Acta2 R258C mutation on the SMC phenotype, with increasing phenotypic severity
when wildtype: mutant α-actin levels are decreased.
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CHAPTER ONE: Introduction

1

Thoracic Aortic Aneurysms and Aortic Dissections (TAAD)

Epidemiology
Thoracic aortic aneurysms and dissections (TAAD) are the eighteenth leading cause
of death in the United States (thirteenth leading cause in people over 65 years of age), and
they account for approximately 15,000 deaths every year (1). Aortic dissections are medical
emergencies – if left untreated, they cause death in about ⅓ of all patients within 24 hours of
the onset and 75% of patients within two weeks (2), with a death rate of approximately 1%
per hour from the onset of the dissection (3; 4).
An aortic aneurysm is an enlargement of the vessel wall, which can progress to a
dissection – a tear in the wall that creates a false lumen and diverts the blood flow away
from the main channel (2-3; 5-6). Aortic aneurysms are classified based on the region of the
aorta where they form - the aortic root, ascending aorta, aortic arch, descending aorta, or
abdominal aorta (1; 3; 5-6). Ascending, descending and aortic arch aneurysms are also
commonly referred to as thoracic aortic aneurysms. Aortic dissections, on the other hand,
have two separate classification systems that are commonly used – the Stanford system and
the DeBakey system. A Stanford type A dissection is one of the ascending aorta, the aortic
arch or the descending aorta, which originates in the ascending aorta or aortic arch. Stanford
type B dissections originate in the descending aorta (1-4). A DeBakey class I dissection is an
expansive dissection that originates in the ascending aorta; class II, on the other hand, is a
more localized dissection of the ascending aorta. Class III is dissection of the descending
aorta, which also tends to lead to extensive tearing along the aortic wall (Fig. 1.1) (1-3).

2

Figure 1.1: Thoracic Aortic Aneurysms and Dissections. A. a. Illustration of the locations
along the aorta where aneurysms commonly occur and b. the Stanford and DeBakey aortic
dissection classification systems. Republished with permission of Annual Reviews, from
[Genetic basis of thoracic aortic aneurysms and dissections: Focus on smooth muscle cell
contractile dysfunction. Milewicz, D. M., Guo, D. C., Tran-Fadulu, V., Lafont, A. L., Papke,
C. L., Inamoto, S., Kwartler, C.S. & Pannu, H. 9, 2008]; permission conveyed through
Copyright Clearance Center, Inc.
Symptoms of aortic dissection include, but are not limited to, sharp chest pain, which
may radiate as the dissection spreads, sudden drop or, conversely, increase in blood pressure
(distal dissections would cause an increase in blood pressure, while proximal dissections
could lead to either an increase or a decrease), sweating, difficulty breathing, numbness of
limbs, fainting and loss of consciousness (2; 5). Aortic dissections are often misdiagnosed as
heart attacks because of the similarities in the clinical presentation (2; 5). Because
dissections can severely compromise the aortic function and progress to complete rupture
and death, they are treated as medical emergencies, requiring timely surgical intervention
and repair.
The current standard of care for patients with TAAD is a repair surgery (2). The
aorta can be surgically repaired either at the aneurysm stage or after a dissection is found (2;
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5-6). If the aneurysm is discovered early, patients can undergo preventive surgery. However,
as the disease progresses to dissection, the surgery becomes emergent, and survival rates
decrease. Only about 50% of patients with acute dissections make it to the emergency room,
and even fewer are diagnosed in time because of the overlap of the symptoms with other,
more frequent conditions, such as myocardial infarction, heartburn, pulmonary embolism or
pericarditis (2). A simple X-ray cannot rule out the possibility of a dissection; the most
accurate tests for diagnosing an aortic dissection are computer tomography and
transesophageal echocardiograms (2; 4). Even after a dissection is diagnosed and surgery is
recommended, the survival rate remains low because a large proportion of patients who
undergo the repair surgery do not survive the procedure (3). Therefore, it is imperative to
identify patients at risk for a dissection before the onset of the acute event so that they can
be monitored and treated in a timely manner.
Major risk factors for TAAD include hypertension, bodybuilding, and smoking/drug
use (1-3; 5-7). Therefore, lifestyle adjustments and anti-hypertensive drugs such as the betablocker metoprolol are commonly prescribed to patients at risk of aneurysm development
(1-2; 5). If patients cannot tolerate beta-blockers, they are often administered calcium
channel blockers, which also help reduce blood pressure in these patients (1-2). Additional
risk factor is male gender (1-5). There are genetic risk factors as well, such as syndromic
mutations as in Marfan, Loeys-Dietz and vascular Ehlers-Danlos syndromes, and also
congenital abnormalities such as bicuspid aortic valve (BAV). Finally, an aortic dissection
can be a complication as a result of vasculitis, coronary artery bypass graft or cardiac
catheterization (2-3).
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Much work has been done by our lab and others to improve awareness of this
condition and help identify populations, families and individuals who may be at risk of
aortic aneurysms and dissections. The ultimate goal is to be able to diagnose a patient early
and monitor and manage their aneurysm progression so that it cannot proceed to dissection.

Arterial Structure

The walls of all arteries are made up of three layers – the intima, media and
adventitia (2; 5-6; 8). The intima is an endothelial cell monolayer that makes up the
innermost portion of the aortic wall and lines the lumen of the vessel. The media is the
middle layer, and it is made up of elastic fibers and smooth muscle cells arranged in
concentric circles around the lumen (6; 8-9). Between the intima and the media lies an
elastin layer termed “internal elastic lamina,” and between the media and adventitia lies the
“external elastic lamina” (8-9). The adventitia is made up of large amounts of extracellular
matrix components, fibroblast cells and nerve endings (Fig. 1.2A, top). The arterial wall is
further held together by a network of collagens, which provides rigidity to the vessel (8).
There are two kinds of arteries found in the body – small muscular arteries and large
elastic arteries. The carotid arteries are one example of muscular arteries. In these vessels,
the medial layer between the internal and external elastic laminas is entirely composed of
smooth muscle cells without any additional elastin (9). The aorta, on the other hand, is an
example of an elastic artery. It is the largest vessel in the human body, and it carries blood
directly out of the left ventricle of the heart. The aorta’s media is composed of multiple
single-cell-thick layers of smooth muscle cells, lying between layers of elastin fiber. Each
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unit composed of a layer of SMCs between two elastin fibers is called a “lamellar unit” (Fig.
1.2B) (8; 10). The smooth muscle cells (SMCs) are attached to the lamellae via fibrillin 1rich microfibrils and other extracellular matrix proteins such as fibronectin or vitronectin (6;
8). The points of contact of the microfibrils with the SMC plasma membrane are called
dense plaques (or focal adhesions when the cells are grown in culture). Finally, due to its
large size the aorta uniquely has its own network of vessels bringing nutrients to the
adventitial fibroblasts, called the vasa vasorum (8).
Unlike in muscular arteries, the additional elastin in large vessel walls allows these
vessels to resist pulsatile blood flow by providing elastic recoil and by aiding tensile force
generation across the wall. Elastic lamellae are laid during development and remain
unchanged during adulthood regardless of the accumulation of insults to the vessel wall. The
number of elastic lamellae varies depending on the specific region of the vessel – for
example, there are fewer lamellar units in the abdominal aorta compared to the ascending
aorta (8).
Pathological examinations of dissected patient aortas consistently show three
“hallmark” features of the diseased aorta: medial degeneration, loss of elastic fibers and
accumulation of proteoglycans in the medial space (Fig. 1.2A, bottom). Medial
degeneration refers to the disarray of smooth muscle cells in the medial wall. There may be
regions of focal loss of SMCs present in the vessel as well, but it has not been ascertained
yet whether there is a loss of smooth muscle cells with aortic disease progression or, to the
contrary, a gain (5-6; 8). In patients with aortic dissections, the elastic lamellae appear
fragmented, distended or may be missing. Proteoglycans, which are heavily glycosylated
proteins secreted by nearby cells, accumulate in diseased aortas because they serve to fill
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spaces left as a result of the matrix fragmentation and cellular disorganization (5-6; 8).
Proteoglycans usually appear at the very early stages of aneurysm formation, and can serve
as an early marker for disease (11).

Figure 1.2: Structure and Organization of the Aorta A. Hematoxylin and Eosin staining
and Movat staining of aortic tissue from control (a,c) and TAA patients (b,d) shows the
three-layer organization of the aortic wall. In control patients, cells are neatly arranged
in layers (a) in-between elastic fibers (c, elastin shown in black). In TAA patients, cells
are disorganized (b), and there is a loss of elastin fibers and accumulation of
proteoglycans (c, proteoglycans appear blue). Republished with permission of Annual
Reviews, from [Genetic basis of thoracic aortic aneurysms and dissections: Focus on
smooth muscle cell contractile dysfunction. Milewicz, D. M., Guo, D. C., Tran-Fadulu,
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V., Lafont, A. L., Papke, C. L., Inamoto, S., Kwartler, C.S. & Pannu, H. 9, 2008];
permission conveyed through Copyright Clearance Center, Inc. B. Illustration of a
lamellar unit, composed of elastin fibers, single layer of smooth muscle cells and
microfibrils linking the cells to the fibers. Inset illustrates the smooth muscle contractile
unit. Adapted with permission of Annual Reviews, from [Genetic basis of thoracic
aortic aneurysms and dissections: Focus on smooth muscle cell contractile dysfunction.
Milewicz, D. M., Guo, D. C., Tran-Fadulu, V., Lafont, A. L., Papke, C. L., Inamoto, S.,
Kwartler, C.S. & Pannu, H. 9, 2008]; permission conveyed through Copyright Clearance
Center, Inc.
Finally, studies of TAAD consistently point towards an increase in matrix
metalloproteinases (MMPs), which are Zn ion-dependent enzymes that cleave extracellular
matrix proteins, contributing to the end-stage pathology. Recent work suggests that MMPs
play a key role in the pathogenesis of TAAD, and that treatment of aortas with the nonspecific MMP inhibitor doxycycline can reverse the aneurysm phenotype in rodent models
of disease (7-8; 12).
Taken together, the current understanding of aneurysm pathogenesis is that
accumulation of risk factors, a genetic predisposition, or both, can send stimuli to the SMCs,
causing them to secrete more extracellular matrix proteins, as well as MMPs. This early
change leads to a dysregulation of the extracellular matrix, cleaving of the elastic fibers and
disarray of the SMCs as a result of compromised lamellar units. In the later stages there is
also accumulation of macrophages in the adventitia and potentially, an increase in oxidative
stress, which may cause SMC apoptosis and further increases in MMP activity. Once the
aortic wall integrity is compromised and the elasticity is lost, aneurysms progress even more
rapidly and ultimately proceed to dissection (6; 8).

8

Vascular Smooth Muscle Cells (VSMCs)

Research on TAAD has highlighted the importance of the medial layer of the aorta in
disease onset and progression, with a special focus on vascular smooth muscle cells
(VSMCs) because of their contractile and secretory properties, which contribute to the
TAAD pathology (6).
Quiescent smooth muscle cells are spindle-shaped, and they express high levels of
contractile genes and proteins. Unlike skeletal myocytes and cardiomyocytes, smooth
muscle cells do not contain sarcomeres, but instead they have crisscrossing actomyosin
units, each of which is structured similarly to that in other muscle, with two myosin
molecules sliding along actin filaments with the aid of ATP (13). Each contractile unit is
connected to the others via dense bodies within the cells or via dense plaques at the plasma
membrane. Quiescent smooth muscle cells make up the medial layer of the aorta. They are
able to contract in unison, together with the elastic lamellae, in response to blood flow.
While the elastic lamellae are key to withstanding high stress and strain on the aorta, the
smooth muscle cells are master organizers and serve to guide the contractile response and
force generation in the vessel wall (6; 8; 14).
Smooth muscle cells are unique among muscle cells in that, upon stimulation from
mechanical forces or a range of cytokines, they are able to switch from their quiescent
phenotype to a less contractile but more migratory, secretory and proliferative phenotype
(Fig. 1.3) (14). When smooth muscle cells receive a signal to become dedifferentiated, they
undergo a switch that leads to low contractile gene and protein expression but an increase in
proliferation, migration and the synthesis of collagens and other extracellular matrix
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proteins. This transition is extremely important in response to vascular injury, for example,
because it allows smooth muscle cells to migrate into the damage site, proliferate to produce
more cells and also secrete the necessary factors and extracellular matrix proteins to help
rebuild the injured area of the vessel (14-16). Dysregulation of the smooth muscle
phenotypic switch contributes to a range or pathologies, such as post-angioplasty restenosis
and atherosclerosis (8). In fact, work in our lab suggests that increased smooth muscle cell
proliferation as a result of genetic mutations in a range of genes contributes to diverse
occlusive vascular diseases, such as ischemic stroke, Moyamoya disease or fibrotic earlyonset carotid artery disease (9; 17). Together, these observations have been termed
“hyperplastic vasculomyopathy” (9).

Figure 1.3: Smooth Muscle Cell Phenotypic Plasticity. Reprinted by permission from
Macmillan Publishers Ltd: Genetics in Medicine, (9), copyright (2010).
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SMC phenotype switching
The current paradigm in smooth muscle cell biology is that the SMC phenotype is
controlled by one major signaling axis, the Serum Response Factor (SRF): MyocardinRelated Transcription Factor (MRTF) axis, which integrates mechanical and cytokine cues
and directs the transcriptional changes that induce the subsequent phenotypic switch (14; 1819). SRF is a highly promiscuous and ubiquitously expressed transcription factor, which
binds one or more CArG box elements in the promoter region to activate transcription of
over 200 genes (14; 19-20). SRF interacts with a range of transcriptional cofactors to confer
specificity. One such family of transcription factors that is specific to cardiomyocytes and
smooth muscle cells is the family of myocardin-related transcription factors (MRTFs),
which includes myocardin, MRTF-A (also known as MKL1, which stands for acute
megakaryoblastic leukemia factor 1/ MAL1), and MRTF-B (MKL2) (21). These three cofactors have overlapping but also distinct sets of target genes. Knockout mouse models of
each of the three members of the MRTF family have been generated to help identify the
differences between the three co-factors. Myocd-/- mice exhibit embryonic lethality at day
10.5, due to defects in heart development compounded by additional profound loss of SMCs
in the vasculature (22). MRTF-B-/-mice also die prenatally due to a defect in pharyngeal arch
development; they additionally show a defect in SMC differentiation in the ascending aorta,
specifically in cells of neural crest origin (19; 23-24). MRTF-A-/- mice, on the other hand,
are viable but the mothers cannot nurse their young (19; 24-25).
Two of the three members of the MRTF family, MRTF-A and MRTF-B, have been
found to be able to translocate from the cytoplasm to the nucleus (19; 26). In fact, this
‘shuttling’ of MRTF plays a key role in the regulation of contractile gene expression.
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Monomeric (G) actin can bind to MRTFs in the cytoplasm, sequestering it outside of the
nucleus. When MRTF is out of the nucleus, SRF is free to bind other co-factors such as
ternary complex factor (TCF) or Elk-1 (19; 21; 27), and drive the expression of growthrelated genes. In order for differentiation to be induced, actin polymerization triggered by
the small G-protein RhoA is required; this triggers the translocation of MRTFs to the
nucleus (19; 21; 26; 28-29). Once in the nucleus, MRTFs bind SRF and promote the
expression of contractile and cytoskeletal markers, causing a positive feedback loop to
reinforce the differentiation signal. Importantly, while myocardin also binds SRF and drives
contractile gene expression, it is constitutively nuclear (26; 30) and does not respond to Rhoactivated actin polymerization (30), but is regulated by the ubiquitin proteasome system
(31).

Regulation of actin polymerization
There are six types of actin in the human body, and four of those are found in smooth
muscle cells, which together make up approximately 40% of total smooth muscle protein:
smooth-muscle specific α-actin, cytoskeletal β-actin, and both smooth-muscle specific and
non-muscle γ-actin, all of which share over 95% homology (32). Smooth muscle-specific αactin the most abundant of all forms – approximately two thirds of all actin in SMCs is αactin, compared to β-actin (21%) and γ-actin (12%), and it localizes with myosin in the
smooth muscle contractile units (32, 33). Cytoskeletal filaments, on the other hand, are
predominantly composed of γ-actin, and β-actin is most frequently cortically localized (32).
Actin polymerization plays a key role in mounting the SMC response to tension, and
it involves both cytoskeletal changes and contractile filament formation (32; 34). According
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to the classical understanding, actin polymerization is initiated when actin monomers bind
ATP, which activates them and promotes the formation of oligomers first and then a cluster
of actin molecules, or a nucleus. This nucleus of polymerization recruits more ATP-bound
actin and elongation occurs. As actin is stabilized in the filament, ATP hydrolysis occurs
and actin remains ADP-bound (35). A filament usually remains stable with the aid of
capping and stabilizing proteins like calponin, or tropomyosin, and it is considered that the
ADP-bound, older actin filaments are less stable than the younger, ATP-bound filaments
(36-37). Interestingly, Kueh and colleagues (2008) suggest that that the ADP-bound form is
in fact more stable because it allows for a canonical helix to form. The mature filament,
however, is targeted much more frequently by cofilin, the binding of which reintroduces
disorder in the helix and causes an increase in the filament shrinking rates (36).
A major regulator of actin filament formation and contractility in vascular SMCs is
the small G-protein RhoA (29; 34; 38-40). Activation of RhoA can be driven by upstream
signaling cues, for example by activated focal adhesion kinase (FAK) (39), angiotensin II
type 1 receptor (41), or activated integrin-linked kinase (ILK) (29), which in turn are
promoted by mechanical stress (29) or individual extracellular matrix components (40).
RhoA regulates polymerization via induction of mDia, and p160ROCK, a Rho kinase, which
activates LIM kinase (LIMK) and, in turn, cofilin, leading to actin reorganization. Further,
Rho kinase inhibits the myosin light-chain phosphatase, allowing for myosin light chain
phosphorylation to persist and thus increasing contractile filament crosslinking in the SMCs
(29; 39). Thus, RhoA controls actin reorganization, contractility, and contractile gene
expression via the SRF: MRTF axis, making it a key regulator of the SMC phenotype (19;
28).
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While RhoA is important for regulating actin reorganization in differentiated
vascular SMCs, other small G-proteins can also regulate actin polymerization in migratory
cells, for example, where turnover of actin filaments and cytoskeletal rearrangements are
rapid and transient. Such regulatory G-proteins include Rac1 and Cdc42, which, together
with RhoA, are localized in the focal adhesions and activated in response to the changing
composition of these adhesions (39).

Focal adhesions
Focal adhesions are the points of contact between the plasma membrane and the
extracellular matrix. Clustered around integrin receptor heterodimers, focal adhesions are
multi-protein complexes, which are important for both signal- and mechano-transduction in
SMCs. Focal adhesions act as “sensors” for mechanical stretch, and they trigger the
activation of signaling cascades involved in proliferation, migration, survival, and
cytoskeletal remodeling (39; 42). Focal adhesions are not static; instead they can “mature”
in response to cues from actin polymerization and myosin force generation (43-44). During
focal adhesion maturation, the adhesions not only become larger and more complex, but
they also change in composition (44-45). For example, Kuo et al (2011) showed that treating
fibroblast cells with blebbistatin, which inhibited myosin motor function, caused adhesions
to appear smaller (less mature) and enriched in Rac1 activators, unlike untreated cells, which
had mature focal adhesions, differentially enriched in RhoA activators. Enrichment with
Rac1 activators promotes proliferative signaling and prevents further focal adhesion
maturation; enrichment in RhoA activators in more mature adhesions, on the other hand,
promotes further actin polymerization, cytoskeletal remodeling and further focal adhesion
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maturation (38; 46-47). We were able to replicate the findings by Kuo and colleagues
(2011) in SMCs with a myosin mutant, which caused a decrease in myosin function:
compared to wildtype SMCs, the SMCs with impaired myosin function had increased Rac1
activation, decreased RhoA activation, smaller focal adhesions and a dedifferentiated
phenotype; the differentiated phenotype was restored by activating RhoA in these cells (48).
Thus, focal adhesions play a key role in regulating the SMC phenotype and response to the
environment by mediating interactions with the extracellular matrix and responding to actin
polymerization and signaling cues within the cells.

Embryonic origins of VSMCs
Because smooth muscle cells are widely distributed in a number of organs and organ
systems, they also have diverse embryonic origins. Even different segments of the aorta are
populated by SMCs of distinct embryonic origins (49). For example, the aortic root is made
up of secondary heart field-derived SMCs, the ascending aorta, aortic arch and the base of
the left and right carotid arteries, right subclavian artery and the innominate artery are made
up of neural crest cell-derived SMCs, while the descending aorta contains SMCs originating
from somite cells, and the abdominal aorta is made up of mesodermally-derived cells (49).
Studies of the SMC properties in the different regions of the aorta suggest that there is a
differential response to common cues, such as TGF-β1: a study by Gadson et al (1997), for
example, established that although both neural crest-derived and mesoderm-derived SMCs
required TGF-β1 for contraction in a collagen gel contraction study, the response was much
greater in mesoderm-derived SMCs. Furthermore, when administered at the same
concentrations, TGF-β1 was able to induce proliferation in neural crest-derived SMCs but
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caused growth arrest in mesoderm-derived SMCs (49; 51). Further, studies involving the
translocation and grafting of different cell types in other portions of the aorta suggest that
the basis of SMC phenotype and behavior depends on embryonic origin and not on
environmental factors. Taken together, these findings add another layer of complexity when
studying SMC function and dysregulation in disease and set a requirement for cell-lineage
specific studies.

Genetic Basis of TAAD

TAAD is a clinical feature of several syndromes (Marfan syndrome, Loeys-Dietz
syndrome, vascular Ehlers-Danlos syndrome); it can also be inherited in the absence of
syndromic features (termed familial TAAD, or FTAAD), or can occur sporadically (termed
STAAD). Syndromic cases account for 5% of all aortic dissections; familial cases are
approximately 15%, and the rest are sporadic (3; 5-8; 52).

Syndromic presentation
TAAD is a common and fatal outcome for patients with Marfan syndrome (MS),
Ehlers-Danlos type IV (vascular EDS, or vEDS), and Loeys-Dietz syndrome (LDS).
Additional syndromes that may lead to TAAD include filamin A deficiencies, arterial
toruosity syndrome (caused by mutations in the glucose transporter GLUT10), and bicuspid
aortic valve (BAV) syndrome (3; 5; 8). Specific findings related to several of these
syndromes in relation to TAAD are presented below.
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Marfan syndrome is a common connective tissue disorder, which affects
approximately one in 5000 newborns in the United States (53-54). Patients with Marfan
syndrome present with a range of skeletal features (great height, extremely long limbs,
pectus excavatum - sunken chest, cleft palate), as well as pulmonary, ocular and
cardiovascular symptoms (53-54). Upon examination, the aortas of patients with Marfan
syndrome reveal a loss of SMCs, loss of elastin, and an increase in MMPs. The causal gene
defect was identified in patients with Marfan syndrome in 1991– a dominant negative
mutation in FBN1, which codes for the extracellular matrix protein fibrillin (5-6; 8). Fibrillin
is the main constituent of microfibrils, which connect the layers of elastin to the smooth
muscle cell layers in the media. Fibrillin mutations lead to a defect in transforming growth
factor beta (TGF-β1) signaling: TGF-β1 is normally sequestered by fibrillin in the
extracellular matrix in an inactive form (6; 54). Fibrillin mutations prevent the sequestration
of TGF-β1 and thus lead to enhanced TGF-β1 signaling, which affects multiple pathways in
smooth muscle cells and adventitial fibroblasts. It has been proposed that dysregulated TGFβ1 signaling drives aortic aneurysm formation in MS patients (8; 55). A National Institutes
of Health clinical trial is currently underway for patients with Marfan syndrome after
promising results were obtained from mouse models of the disease, which showed a
dramatic reversal of aneurysms when treated with losartan, an angiotensin II receptor
blocker (54). While the benefits of the losartan treatment have been established in mice
carrying a mutation in Fbn1, the exact mechanism by which an angiotensin receptor II
blocker mediates TGF-β1 blockade is not yet clear (55). More recently, another FDAapproved drug, pravastatin, was also shown to reverse Marfan aneurysms to a similar extent
as losartan, albeit without preserving the aortic architecture as well as losartan (56).
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Loeys-Dietz syndrome is caused by mutations in the TGFBR1/2 genes, and affects
approximately 500 people worldwide, with the number increasing as knowledge about this
condition, first identified in 2005, is spreading (57-58). Common features in patients with
the disease include wide-set eyes, translucent and thin skin, bifid uvula, cleft palate, as well
as early-onset aortic disease (1; 3; 8; 57; 59). Interestingly, patients with Loeys-Dietz
syndrome, display very similar clinical features to patients with Marfan syndrome, as well as
dysregulated TGF-β1 signaling in spite of the fact that the identified mutations have a
predicted loss of TGF-β1 receptor function (6; 8). Experiments using losartan and
pravastatin are currently underway to evaluate their potential benefit for LDS patients in
addition to Marfan syndrome patients.
Finally, vascular Ehlers-Danlos syndrome (vEDS) is caused by a mutation in
procollagen 3, encoded by the gene COL3A1, and it affects as many as 1 in 5000 people (1;
6). Patients with vEDS have thin, translucent skin and impaired wound healing, joint
hypermobility and distinctive facial features, including large protruding eyes, small chin,
thin lips and nose. These patients frequently present with spontaneous aortic dissections or
organ rupture without prior history of aneurysms (3; 6; 8). It has been suggested that the
dissections occur at focal points as a result of accumulation of environmental insults to the
same site, such as hypertension or physical injury (8). In 2010, Ong et al reported a clinical
trial conducted in France and Belgium using the β2-adrenergic receptor blocker and β1
activator celiprolol for the treatment of patients with vEDS. Use of celiprolol led to a
threefold decrease in the frequency of deadly events in patients with vEDS (60).
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Sporadic TAAD
A patient with sporadic TAAD is one who presents with an aortic aneurysm or
dissection without prior family history and who does not carry any of the Mendelian
mutations associated with syndromic or familial TAAD. Sporadic TAAD is by far the most
common form of TAAD among patients. These patients are usually older, and it is believed
that a combination of genetic and environmental factors, and the accumulation of insults to
the aorta with time, might jointly contribute to disease. The most common environmental
risk factor is hypertension, followed by smoking and obesity (6). STAAD patients are at a
great risk because currently there are no proven strategies for recognizing who in the general
population might carry a predisposition for developing an aortic dissection.
Our lab and others have been working to identify the genetic risk factors associated
with sporadic TAAD, focusing on rare variants that are found in patient cohorts but not in
controls. Rare variants are genetic events, which are not as frequent in the general
population as single nucleotide polymorphisms (SNPs), but are more prevalent than
Mendelian mutations. Rare variants do not necessarily segregate with disease in families,
and could be found at lower frequencies among healthy individuals too; thus, rare variants
might contribute to the development and predisposition to TAAD, but they are unlikely to
cause disease without any additional risk factors (48; 61- 62).
So far we have identified two kinds or rare variants - copy number variations
(CNVs) and missense alterations. While a number of CNVs were identified in patients with
sporadic disease, they all disrupted very few and specific pathways, most frequently genes
related to contraction and focal adhesions (61). One such example is a copy number
variation in a region on chromosome 16p13.1, which was present in approximately 1% of
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patients in the STAAD cohorts studied, but only in 0.09% of control cohorts. Interestingly,
this duplication was also present in some patients with family history of the disease, though
it did not segregate with disease in these families. The 16p13.1 region comprises a number
of genes, but the most likely candidate for increasing the risk of dissection in sporadic
TAAD patients is the variation in MYH11, the gene that codes for smooth-muscle myosin
heavy chain, an essential component of the acto-myosin contractile apparatus in vascular
smooth muscle cells (62). The pathways, which could cause smooth muscle cell dysfunction
and thus greater risk for an aortic aneurysm and dissection as a result of the increased
MYH11 copy number, are currently being elucidated.
A second rare variant that we chose to characterize is a missense R247C alteration,
also in MYH11. This alteration was enriched in TAAD cohorts, as well as cohorts of patients
with occlusive vascular disease, and it was predicted that it leads to a 10-12 fold increase in
the risk for a dissection in these individuals. Interestingly, a paralogous mutation in cardiac
myosin, MYH7, R249Q, has already been characterized in cases of hypertrophic
cardiomyopathy, supporting the hypothesis that the MYH11 R247C alteration could
contribute to TAAD. Indeed, a double knock-in mouse model of the R247C alteration
showed decreased aortic contractility ex vivo and decreased ATPase activity in vitro, but it
did not develop aortic disease. Myh11R247C/R247C mice also exhibited a pathologic highly
proliferative response to carotid artery injury by carotid artery ligation. Further, explanted
primary aortic smooth muscle cells from these mice were dedifferentiated and significantly
more proliferative. These SMCs also had smaller focal adhesions and increased expression
of focal adhesion kinase (FAK) and Rac1, but decreased RhoA activation. Treating the cells
with the bacterial endotoxin CN03 caused RhoA to become constitutively activated, which

20

was able to rescue the de-differentiated phenotype of the smooth muscle cells. Therefore,
although the Myh11 R247C missense mutation did not confer an aortic disease phenotype, it
appeared to increase the risk of an aortic event by affecting the smooth muscle cell
phenotype and aortic contractility and the risk of an occlusive vascular event by leading to
increased proliferation in response to injury in vivo (48).
Finally, LeMaire and colleagues (2011a) conducted a genome-wide association study
of patients with STAAD, looking at common genetic variants, which may increase the risk
for aortic disease, and found such (SNPs) on chromosome 15q21.1, a region that
encompasses FBN1, the gene coding for fibrillin 1, and causes Marfan Syndrome. This
finding draws yet another link between the different presentations of TAAD and suggests
that lessons from the study of syndromic patients may be applicable to TAAD patients at
large, and that extracellular matrix defects and smooth muscle contractile defects likely
share similar downstream effects, resulting from the dysregulation of the smooth muscle cell
phenotype.

Familial TAAD
About 15% of patients with aortic aneurysms and dissections have first-degree
relatives with the condition. These patients have single gene mutations, which are dominant
negative and have variable expression and decreased penetrance (3; 5- 6; 8; 52). Our lab and
others have identified a number of genes that cause familial TAAD, which broadly segregate
in two categories – TGF-β1-signaling pathway genes and contractile genes.
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Role of impaired TGF-β1 signaling in FTAAD
Transforming growth factor beta is a potent and versatile cytokine, which has a role
in development and regulates a number of different cell types in adult tissues. TGF-β1
signals through its receptors, TGFBR-1 and -2, via two pathways. The canonical TGF-β1
pathway causes the activation of regulatory Smads (Smad2 and Smad3), which dimerize and
associate with Smad4 in order to translocate into the nucleus where they drive the
expression of a number of genes. Non-canonical TGF-β1 signaling is independent of Smad
activation, and it results in the activation of a number of different mitogen-activated protein
kinases (MAPKs). In total, TGF-β1 drives a range of cellular processes, which in smooth
muscle range from differentiation to proliferation, migration and survival. TGF-β1 is an
autocrine and paracrine signal, and it is found in an inactive form in complex with Latency
Associated Peptide (LAP) and Latent TGF-β1-Binding Protein (LTBP), which together form
a Large Latent Complex (LLC) and associate with microfibrils in the extracellular matrix
(8).
So far, we have identified three genes which are altered in our families and belong to
the TGF-β1 pathway: TGFBR1, TGFBR2, and SMAD3. TGFBR1/2 mutations account for
approximately 1-2% of the families with inherited TAAD; these mutations lead to LoeysDietz syndrome in some patients, but they do not lead to syndromic presentation in the
studied families (5; 64). These mutations cause early-onset aortic disease, medial disarray,
loss of elastin fibers in the aortic wall and dedifferentiation of SMCs. Interestingly, these
SMCs are also less proliferative than wildtype SMCs. While canonical signaling was not
significantly altered, non-canonical signaling through p38 MAPK and Akt was decreased,
but the exact mechanism has not been determined (64).
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Mutations in SMAD3 are responsible for about 2% of all cases of FTAAD (5; 65).
Interestingly, in addition to aortic disease, some of the TAAD families carrying alterations
in this gene have also had history of aneurysms in other vessels. Even though the changes
occurring in the vascular SMCs of patients with SMAD3 mutations have not yet been
characterized, aortic tissue from these patients indicates an increase in SMAD3 staining, as
well as in phosphorylated SMAD2. These observations were not consistent with data from
Smad3-/- fibroblasts, which point towards a dedifferentiated phenotype, with cells expressing
low levels of downstream canonical TGF-β1 targets, such as connective tissue growth factor
(CTGF) and collagens (65). While the reason for the discrepancy has not been clarified yet,
it highlights the level of complexity that is added when interactions with other cell types and
the extracellular matrix are taken into consideration.

Role of contractile gene mutations in FTAAD
So far mutations in three contractile genes have been identified in families with
FTAAD - MLCK, MYH11 and ACTA2, which together account for approximately 13% of all
cases of FTAAD.
MLCK (also known as MYLK) is the gene for myosin light-chain kinase, a
serine/threonine kinase, which is responsible for the phosphorylation of myosin regulatory
light chain at Ser19 and the activation of the smooth muscle-specific, as well as nonmuscle,
myosin motors for acto-myosin contraction. Two mutations have been identified in families
with TAAD, indicating that MLCK mutations are responsible for approximately 1% of
FTAAD cases. Interestingly, patients with mutations in MLCK develop acute aortic
dissections without developing aortic aneurysms first (66).
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Mutations in MYH11 are responsible for approximately 1-2% of FTAAD and are
consistently identified in conjunction with patent ductus arteriosus (PDA) (67-69). These
mutations cause medial degeneration, SMC disarray as well as focal SMC hyperplasia, loss
of elastic fibers, accumulation of proteoglycans (67-69). Interestingly, Pannu et al (2007)
also reported an increased vascularization in the aortic wall, with the vasa vasorum
penetrating as far as the medial layer, as well as occlusions of the vasa vasorum itself, which
stained positively for SM alpha-actin, indicating that the occluding cells were smooth
muscle-like. Finally, in addition to predisposing to TAAD, MYH11 mutations were found to
segregate with occlusive vascular disease in the families reported by Pannu et al (2007),
indicating a contribution to occlusive pathology in addition to aneurysm formation.
The most commonly mutated gene in families with TAAD is ACTA2, which codes
for smooth muscle-specific α-actin (70). It is altered in approximately 10% of all families
with history of TAAD. Many mutations have been identified in α-actin to date, which are all
predicted to have a dominant negative effect (17; 69-76). Recently, a de novo and extremely
severe ACTA2 R179H/L mutation was identified, which predisposes to multi-system SMC
dysfunction (72).
Similar to MYH11 mutations, ACTA2 mutations also lead to focal hyperplasia and
smooth muscle cells disarray in the aortic wall, coupled with loss of elastin fibers,
proteoglycan accumulation and occlusion of the vasa vasorum by smooth-muscle α-actinpositive cells (Fig.1.4A) (70). Importantly, ACTA2 mutations in FTAAD families also
segregate with a range of occlusive vascular diseases such as livedo reticularis (vascular rash
resulting from occlusions in dermal capillaries), iris flocculi (pigmentation tumors of the
iris), Moyamoya disease (MMD; early-onset cerebrovascular disease, which leads to vessel
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occlusion, compensatory but insufficient microvascularization at the site of occlusion and
stroke), early-onset stroke and early-onset fibrotic coronary artery disease (CAD; Fig. 1.4B)
(17; 70). Detailed analysis of family history also reveals that different mutations in ACTA2
predispose to different but distinct sets of occlusive diseases. For example, patients with
R149C mutations more frequently develop early-onset CAD, unlike patients with R258H/C
mutations, who show a higher frequency of early-onset stroke (17). Therefore, despite
shared aortic pathology, specific mutations can also lead to unique but equally devastating
additional pathologies.

Figure 1.4: Mutations in ACTA2 Lead to TAAD and Vascular Occlusive Diseases. A.
Aortic pathology in patients with two different ACTA2 mutations. Both show proteoglycan
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accumulation (in blue), loss of elastin fibers, SMC disarray. B. The vasa vasorum of patients
with ACTA2 mutations is completely occluded (top panel) with cells that stain positive for
α-actin (bottom panel), indicating these cells are smooth muscle-like. Reprinted by
permission from Macmillan Publishers Ltd: Nature Genetics, (70), copyright (2007).
While the reasons for the different occlusive pathologies associated with each
ACTA2 mutation have not been determined, the cause most likely relates back to the threedimensional α-actin structure and the specific conformational and functional defect that each
mutation confers. Actin monomers consist of four subdomains, each of which plays a
specific role in ATP binding, protein-protein interactions and filament formation (17; 70).
Work on cardiac actin (ACTC1), mutations in which predispose to familial hypertrophic and
dilated cardiomyopathies, indicates that mutations in subdomains 1 and 4 affect the ability
of cardiac actin to interact with other proteins, while mutations in subdomain 3 affect actin
filament formation (77). In smooth muscle-specific α-actin, mutations that confer a greater
risk for developing premature CAD, such as R149C and R118Q, are all found in the
hydrophobic cleft of the actin molecule (17; 70). The ACTA2 R258C/H mutation, on the
other hand, is found in subdomain 4 of α-actin, which plays a role in the opening and closing
of the ATP binding pocket (17; 70). It has not yet been properly studied how each mutation
alters the ability of smooth muscle actin to bind other molecules, such as calponin, cofilin,
gelsolin or profilin, which regulate actin filament polymerization, severing or stability.
Recent work by Bergeron et al (2011) was the first to identify specific changes resulting
from different ACTA2 mutations found in TAAD patients by studying two neighboring
mutations using a S. cerevisiae expression system. The authors compared the N115T and
R116Q mutations found in patients with TAAD, and found striking differences in nucleotide
exchange rates and in sensitivity to severing proteins like cofilin, where the N115 mutation
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was hyposensitive, and the R116Q mutant was hypersensitive (78). These are only two
examples in a large field that is yet to be explored in more detail.

Role of ACTA2 in TAAD Pathogenesis

Since ACTA2 was identified as a common cause of familial TAAD, work in our lab
has focused on determining the mechanisms of disease pathogenesis in patients with ACTA2
mutations using primary aortic smooth muscle cells and dermal fibroblasts from patients, as
well as mouse models.
Staining for α-actin in smooth muscle cells explanted from the aortas of patients with
ACTA2 mutations confirm a dominant negative effect of the ACTA2 mutations on contractile
filament formation. In fact, polymerization of α-actin into actin filaments is disrupted to a
different extent in all mutations (Fig. 1.5A). Alpha-actin polymerization was similarly
disrupted in explanted patient dermal fibroblasts, which were treated for 72 hours with TGFβ1 to induce transformation into myofibroblasts and, consequently, contractile protein
expression. Further, both SMCs and fibroblasts were shown to proliferate significantly more
than cells obtained from age-, race- and gender-matched normal controls (Fig. 1.5B) (70).
These observations are in agreement with the vascular pathology observed by
immunohistochemistry (Fig. 1.4) (17; 70). Together, these findings led to the hypothesis that
the effects of ACTA2 mutations are twofold. First of all, mutations in ACTA2 lead to
decreased contractility in the aorta by disrupting the SMC contractile apparatus and, hence,
mechanotransduction across the medial layer (6). In addition, ACTA2 mutations cause a

27

hyperplastic compensatory response in smaller arteries, where SMCs are solely responsible
for maintaining the contractility of the vessel, leading to vascular occlusive disease (9).

Figure 1.5: Pathology of Cells from Patients with ACTA2 Mutations. A. SMCs from
patients with ACTA2 mutations have disrupted α-actin filament formation. Adapted by
permission from Macmillan Publishers Ltd: Nature Genetics, (70), copyright (2007) B.
Explanted SMCs and dermal fibroblasts from patients with ACTA2 mutations proliferate
more than control cells in culture. Reprinted from The American Journal of Human
Genetics, 84, Dong-Chuan Guo, Christina L. Papke, Van Tran-Fadulu, Ellen S. Regalado,
Nili Avidan, Ralph Jay Johnson, Dong H. Kim, Hariyadarshi Pannu, Marcia C. Willing,
Elizabeth Sparks, Reed E. Pyeritz, Michael N. Singh, Ronald L. Dalman, James C. Grotta,
Ali J. Marian, Eric A. Boerwinkle, Lorraine Q. Frazier, Scott A. LeMaire, Joseph S.
Coselli, Anthony L. Estrera, Hazim J. Safi, Sudha Veeraraghavan, Donna M. Muzny,
David A. Wheeler, James T. Willerson, Robert K. Yu, Sanjay S. Shete, Steven E. Scherer,
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C.S. Raman, L. Maximilian Buja, and Dianna M. Milewicz, Mutations in Smooth Muscle
Alpha-Actin (ACTA2) Cause Coronary Artery Disease, Stroke, and Moyamoya Disease,
Along with Thoracic Aortic Disease, 617-627, Copyright (2009), with permission from The
American Society of Human Genetics.
Characterization of the ACTA2 R258C Mutation Using a Transgenic Mouse Model

Because only limited patient smooth muscle cells samples are available, and because
dermal fibroblasts present a limited alternative system, we proceeded to study the disease
phenotype caused by individual mutations by using a transgenic mouse model carrying
mutations in Acta2.

Figure 1.6: ACTA2 R258C Segregates with TAAD and Premature Stroke in Three
Families. Reprinted from The American Journal of Human Genetics, 84, Dong-Chuan Guo,
Christina L. Papke, Van Tran-Fadulu, Ellen S. Regalado, Nili Avidan, Ralph Jay Johnson,
Dong H. Kim, Hariyadarshi Pannu, Marcia C. Willing, Elizabeth Sparks, Reed E. Pyeritz,
Michael N. Singh, Ronald L. Dalman, James C. Grotta, Ali J. Marian, Eric A.
Boerwinkle, Lorraine Q. Frazier, Scott A. LeMaire, Joseph S. Coselli, Anthony L. Estrera,
Hazim J. Safi, Sudha Veeraraghavan, Donna M. Muzny, David A. Wheeler, James T.
Willerson, Robert K. Yu, Sanjay S. Shete, Steven E. Scherer, C.S. Raman, L. Maximilian
Buja, and Dianna M. Milewicz, Mutations in Smooth Muscle Alpha-Actin (ACTA2) Cause
Coronary Artery Disease, Stroke, and Moyamoya Disease, Along with Thoracic Aortic
Disease, 617-627, Copyright (2009), with permission from The American Society of Human
Genetics.
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We chose to characterize the R258C/H mutation first. This mutation was first
identified in three families, in which over 70% of the mutation carriers developed aortic
disease and approximately 50% had history of early-onset ischemic strokes (starting as early
as 5 years of age; Fig. 1.6) (17). A cDNA construct was generated using the Acta2 gene with
the R258C mutation in exon 7 and a wildtype smooth muscle ACTA2 promoter up to intron
1, attached to the remaining construct at an AatII site. A HindIII site at the 3’ UTR region
containing a neomycin resistant gene was also included (Fig. 1.7A) (79). Using the smooth
muscle α-actin-specific promoter allowed for the transgene to be expressed together with
wildtype actin exclusively in cells that express this actin isoform. In addition, a second,
independent transgenic line was generated to verify that the observed phenotype was not due
to a disruption at the site of transgene insertion but by the transgene itself (Appendix 1 &
2). Further, mutant α-actin expression was confirmed by quantitative real-time PCR and by
isoelectric focusing (IEF) blot using aortic tissue protein (Fig. 1.7B), which was able to
resolve the mutant from wildtype protein.
Next, the mice carrying the transgene on a wildtype background were bred with
Acta2-/- mice so that in two generations, three different genotypes were obtained: Acta2+/+
R258C TG

, Acta2+/- R258C TG and Acta2-/- R258C TG (Fig. 1.7C) (81). Aortic tissue protein was then

isolated from the Acta2-/- R258C TG mice and immunoblotted for SM α-actin in order to show
that the mutant protein is expressed (Fig. 1.7D). Thus, three different mouse models were
developed with a transgene under a wildtype promoter so that mutant actin expression is
tissue-specific and occurring simultaneously with the wildtype expression, and the mutant
protein expression was confirmed by qPCR, immunoblot, and IEF blot.
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Figure 1.7: Generation of the Acta2 R258C TG mice. A. Construct design for mutant
transgene, containing a wildtype α-actin promoter up to intron 1. From J. Cao, MD, PhD
(79), with permission B. IEF blot confirming mutant α-actin expression in the aorta. From
A. Chang, PhD (80), with permission C. Breeding scheme for generating Acta2+/- R258C TG
and Acta2+/- mice. From C. Villamizar (81), with permission. D. Immunoblot showing αactin expression in aortic tissue from Acta2-/- R258C TG mice.
We proceeded to characterize the Acta2+/+ R258C TG and the Acta2+/- R258C TG mice. We
predicted that, like in TAAD patients, the R258C mutation will have a dominant negative
effect and that this disruptive effect will have similar, if less severe, physiological
manifestations in the mice as in the patients, including aneurysm formation and occlusive
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disease phenotype. Further, we hypothesized that decreasing the number of wildtype alleles
in our transgenic mouse models would exacerbate the phenotype.
Characterization of the Acta2+/+ R258C TG and the Acta2+/- R258C TG mice has indicated
that both mice develop aortic enlargements as early as 12 weeks of age, but the difference
from the normal controls was significant only for the Acta2+/-

R258C TG

aortas (Fig. 1.8C)

(81). The number of elastic lamellae laid at development was also significantly larger in
these mice compared to the other genotypes. Interestingly, both Acta2+/+

R258C TG

and the

Acta2+/- R258C TG mice have significantly increased cell density, which, decreases by 24 weeks
of age but remains significantly greater than wildtype medial cell density (Fig. 1.8A,B) (81).
Importantly, aortic contractility in the Acta2+/+ R258C TG SMCs was significantly lower in the
thoracic and ascending aortas compared to the wildtype controls (Fig. 1.8D) (82). This
finding provides evidence towards a dominant negative effect of the mutation on the whole
aorta structure and function.
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Figure 1.8. Aortic Pathology of the Acta2+/+ R258C TG and Acta2+/- R258C TG Mice. A. H&E
and Movat staining of aortas from wildtype, Acta2+/+ R258C TG, Acta2+/- and Acta2+/- R258C TG
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mice at 12 weeks. From C. Villamizar (81), with permission. B. Quantification of number
of lamellae at 4 weeks, medial area and cell density from staining over 6 months. From C.
Villamizar (81), with permission C. Aortic diameter determined by echocardiography up to
1 year of age. From C. Villamizar (81), with permission. D. Aortic contractility is
significantly decreased in the ascending and thoracic aorta of Acta2+/+ R258C TG mice. From J.
Huang, PhD (82), with permission. *p<0.05, **p<0.01.
In order to assess whether the Acta2+/+

R258C TG

and the Acta2+/-

R258C TG

mice

exhibited a pathologic proliferative response in vivo, we used a carotid artery ligation model,
first described by Kumar & Lindner (1997). Briefly, the left carotid artery of mice is ligated
completely proximal to the bifurcation, causing extensive aortic remodeling and neointima
formation, which occludes up to 80% of the lumen in normal mice (83). Importantly, the
cells that make up the neointima are smooth muscle cells that migrate from the media into
the lumen and proliferate extensively. Thus, the carotid artery ligation model assesses the
vascular response to injury in mice. Aortic remodeling and neointima formation are
characterized and quantified when mice are sacrificed for histology 21 days later, with the
right carotid artery serving as control. When we performed carotid artery ligations and
quantified the neointima development 21 days post-injury, we found that the Acta2+/- R258C TG
mice had significantly more neotintima formation compared to wildtype, as estimated by the
area of the intima, of the media and the ratio of the media to the neointima. The Acta2+/+
R258C TG

mice did not have a significant pathologic response to injury (Fig. 1.9A,B) (81). Yet,

it was in the Acta2+/+

R258C TG

mice that we recorded two cases of spontaneous stroke.

Unfortunately, we were unable to preserve the tissue and perform a necropsy to identify the
exact location of the occlusion.
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Figure 1.9: Neointima Formation Following Carotid Artery Ligation in Acta2+/+ R258C TG
and Acta2+/- R258C TG Mice. A. Carotid artery ligation lead to severe occlusions in the
Acta2+/+ R258C TG and Acta2+/- R258C TG mice. B. Medial area, neointima area and the ratio of
the media to neointima are significantly increased in Acta2+/- R258C TG mice, but not in the
Acta2+/+ R258C TG mice. **p<0.01. From C. Villamizar (81), with permission.
To summarize, while the Acta2+/+ R258C TG mice have a slight aortic dilatation, they do
not develop aneurysms, nor do they show a significant hyperproliferative response as a
result of vascular injury. However, they have decreased aortic contractility, increased cell
density by 8 weeks and a rare occurrence of strokes. The Acta2+/- R258C TG mice do not have a
recorded case of stroke so far, but they show robust aortic dilatation starting at 12 weeks of
age, significantly greater number of elastic lamellae, significantly increased cell density and
a significant, pathologic increase in neotintima formation after injury. This data confirms a
dominant negative effect of the mutation, highlights similarities in the pathological
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hallmarks in the mouse models and the human patients, as well as between the Acta2+/+ R258C
TG

and Acta2-/- mice, and robust evidence for the increased severity of the phenotype with the

loss of one wildtype Acta2 allele.
The in vivo phenotype of mice with the R258C mutation posed the question whether
these findings could be translated to the aortic SMCs, too. That lead us to hypothesize that
introducing a mutation in α-actin will lead to (1) impaired filament formation, (2) altered
focal adhesion maturation and (3) increased proliferation. Further, we predicted that the
decrease in relative wildtype to mutant α-actin content would exacerbate the disease
phenotype of the aortic SMCs of these mice as well.
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CHAPTER TWO: Materials and Methods
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Aortic SMC Isolation

Aortas were isolated from 5- to 8-week old wildtype, Acta2+/+ R258C TG, Acta2+/- R258C
TG

and Acta2+/- mice. Three explants were obtained from the Acta2+/+R258C TG mice, four

explants from the wildtype mice, one from Acta2+/- and one from Acta2+/-

R258C TG

; each

explant was made up of 3-5 mouse ascending or descending aortas. Whole aortas were
obtained under sterile conditions and transferred into biopsy media (Waymouth’s basal
medium, Gibco Life Technologies, Grand Island, NY) and either immediately processed or
stored at 4°C. The ascending aorta was separated from the descending aorta at the start of
the left subclavian artery; the two were then processed and grown separately. The adventitia
was gently shaved off and the aortas were washed consecutively in 70% EtOH, sterile PBS
(Gibco Life Technologies, Grand Island, NY) and aortic biopsy medium (Waymouth’s basal
medium). The tissue was cut into small pieces (≤0.5-1 mm diameter) and incubated for 1418 hours at 37°C in 5 ml aortic biopsy medium with 0.5 mg collagenase type I, 0.095 mg of
elastase type I and 0.125 mg of soybean trypsin inhibitor. The digestion was stopped at the
end of the incubation with 2.5 ml of sterile, filtered fetal bovine serum (FBS; Atlanta
Biologicals, Lawrenceville, GA) and 2.5 ml of complete SMC medium. The cells and tissues
were then spun down, resuspended in complete SMC medium and left in 25 cm2 flasks in an
incubator set at 37°C and 5% CO2.
Experiments were conducted only on cultured SMCs from the ascending aorta.
Wildtype and Acta2+/- cells were used as controls. All cells were no higher than passage 5.
All genotypes were passage-matched for each experiment, and each experiment was
conducted between two and six times. Cells for all experiments were plated on collagen IV-
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coated flasks, plates and dishes. Briefly, collagen IV (Sigma-Aldrich, St. Louis, MO) was
resuspended in 0.25% sterile glacial acetic acid and left at 4°C for several hours before use.
The collagen IV stock solution was then resuspended in a 1:19 ratio in sterile PBS. Dishes
were coated and then left to incubate for at least 45 min before cell plating. Extra collagen
IV was removed from dishes before seeding.

SMC Culture and Storage

Smooth muscle cells were grown in 25cm2 and 75cm2 cell culture flasks in
incubators set at 37°C, 5% CO2. Cells were grown in complete smooth muscle medium,
which was made up of Smooth muscle Basal Medium (SmBM, Lonza, Walkersville, MD)
supplemented with 20% fetal bovine serum (FBS; Atlanta Biologicals, Lawrenceville, GA),
2% HEPES (1M), 1% 100x Antibiotic-Antimycotic, 1% 200mM L-glutamine, 1% 100mM
MEM sodium pyruvate (Gibco Life Technologies, Grand Island, NY), as well as growth
factor aliquots: human Fibroblastic Growth Factor (hFGF-B, 1ml), insulin (0.5 ml) and
human Epidermal Growth Factor (hEGF; 0.5 ml; Lonza SmGM-2 SingleQuots,
Walkersville, MD). All components were first filtered through a 0.45 µm sterile filter before
being added to the SmBM. Cells were detached from flasks using 0.25% trypsin (Gibco Life
Technologies, Grand Island, NY) and passed when they reached 80-90% confluency.
Cells were stored in 1 ml aliquots of SMC freeze media (for 50 ml: 40 ml complete
SMC media, 5 ml filtered FBS, 5 ml DMSO (Sigma-Aldrich, St. Louis, MO)) at first in 80°C freezers and then permanently in liquid nitrogen tanks.
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RNA Isolation and Quantitative Real-time PCR

SMCs were seeded on collagen IV-coated dishes and left overnight to attach. They
were subsequently incubated in 1% serum media (serum-starving media: 1% FBS, 2%
HEPES (1M), 1% 100x Antibiotic-Antimycotic, 1% 100x L-glutamine, 1% 100x sodium
pyruvate in SmBM) for 24 hours. The media was then aspirated, and cells were washed once
in PBS, which was completely removed afterwards. Dishes were either placed on ice for
immediate use or stored at -80°C.
For RNA isolation, 1 ml of Trizol (Invitrogen, Carlsbad, CA) was added to each
dish, which was then left on ice for at least 5 min. Cells were detached with a cell lifter and
moved to a centrifuge tube. Two hundred microliters of MB grade chloroform (Fisher
Scientific, Pittsburgh, PA) were added to each tube. Tubes were then shaken vigorously for
15 sec and left to incubate at room temperature for 5 min. The samples were then spun down
at 4°C for 20 minutes at 1,200 x g.
After the cells were centrifuged, the transparent top layer was transferred to a new
centrifuge tube and 750 µL of 100% isopropanol (Fisher Scientific, Pittsburgh, PA) was
added to each tube. Tubes were inverted 20 times and then left either overnight at -20°C or
for 5 minutes at room temperature. Samples were then spun down at 4°C for 30 minutes at
16,100 x g. Once the spin was completed, the liquid was discarded and 750µL of 75%
ethanol (EtOH, Fisher Scientific, Pittsburgh, PA) was added to each tube. The pellet at the
bottom was resuspended by tapping the tube with finger several times, and spun down again
at 4°C and 16,100 x g for 20 min. The EtOH was removed completely and the pellets were
air-dried on ice for 20 min before resuspending in 50 µL of RNase-free water and
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quantifying the RNA concentration at OD 260 nm using a NanoDrop (Thermo Scientific,
Wilmington, DE).
The isolated RNA was then used for cDNA synthesis using High Capacity cDNA
Archive Kit (Life Technologies, Carlsbad, CA) according to the manufacturer’s protocol.
Briefly, 5µL RNA, 5µL 10x RT buffer, 10x random primers, 2.5 µL dNTPs and 2 µL of
Multiscribe RT (50U/µL), together with 30.5 µL RNase-free water were mixed and placed in
a thermal cycler for 10 min at 25°C followed by 2 hrs at 37°C. We used Applied
Biosystems’ TaqMan probes and followed the manufacturer’s protocol when we performed
quantitative real-time PCR of mRNA expression using an Applied Biosystems Prism 7900
HT Sequence Detection System (Applied Biosystems, Foster City, CA). All samples were
run in triplicate and standardized to Gapdh.

Protein Isolation

Cells were grown in 35-mm collagen IV-coated dishes at density of 75,000
cells/dish. After seeding, cells were allowed to attach overnight in complete smooth muscle
medium. They were subsequently serum-starved in 1% serum medium for 24 hours, washed
once in PBS and snap frozen in liquid nitrogen for the preservation of phosphorylated
proteins. Dishes were then stored at -80°C until use. Protein was isolated from cells using
RIPA buffer (50 mM Tris-HCl pH 7.4, 150 mM NaCl, 1% NP-40, 0.25% sodium
deoxycholate, 1 mM EDTA) with 10µL/ml phosphatase inhibitor cocktails 2 and 3 (SigmaAldrich, St. Louis, MO), and 30µL/ml protease inhibitor cocktail (P8340; Sigma-Aldrich, St.
Louis, MO). Between 50 and 100 µL of the solution were added to each dish, depending on
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the dish size. Cells were scraped using cell lifters and the solution was transferred to a
centrifuge tube. Samples were shaken on an orbital shaker at 4°C for 30 min and then spun
down at 16,100 x g at 4°C for 30 minutes. Supernatant was then transferred to a clean tube
and quantified using a standard Bradford assay, measuring absorption at 650 nm. Samples
were stored at -20°C until further use.

Western Blot

Five to ten micrograms of protein sample was loaded onto pre-cast Tris-HCL SDSPAGE gels (BioRad, Hercules, CA), separated by SDS PAGE, and transferred to
polyvinylidene difluoride membranes (Millipore, Bedford, MA) at 35 V overnight or at 80V
for 90 min. Membranes were blocked with 5% (w/v) milk in Tris Buffered Saline with
Tween-20 (TBS-T), and incubated with primary antibodies at their respective concentrations
(see Table 1) on a shaker for 3 hours at room temperature or on a shaker overnight in a 4°C
room. Blots were washed for 10 min in TBS-T before incubating with their respective
horseradish

peroxidase

(HRP)

secondary

antibodies

(Jackson

ImmunoResearch

Laboratories, West Grove, PA) at 1:2,000 concentrations for 1 hour at room temperature.
Immunoblots were then exposed using enhanced chemiluminescence (GE Healthcare,
Piscataway, NJ). Primary antibodies used include anti-α-tubulin, phospho-Akt (S473), total
Akt (all from Cell Signaling Technology, Beverly, MA), anti-SM myosin (Biomedical
Technologies Inc, Stoughton, MA), anti smooth muscle α–actin, anti-calponin (both SigmaAldrich, St. Louis, MO), anti-SM22α (Abcam, Cambridge, MA), anti-GAPDH (Fitzgerald
Industries, Acton, MA), phospho-FAK (Y397) (Millipore, Bedford, MA), total FAK (Santa
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Cruz Biotechnology, Santa Cruz, CA), phospho-PDGFRβ (T1021, Santa Cruz
Biotechnology, Santa Cruz, CA), total PDGFRβ (Cell Signaling Technology, Danvers, MA),
anti-GAPDH (Fitzgerald International Industries, Acton, MA), MRTF-A (C19; Santa Cruz
Biotechnology, Santa Cruz, CA), phospho-p44/42 MAPK (phospho-ERK1/2; Cell Signaling
Technology, Danvers, MA) and p44/42 MAPK (ERK1/2; Cell Signaling Technology,
Danvers, MA). The concentrations at which each antibody was used for Western blot and
immunofluorescent staining are summarized in Table 1. Western blot results were quantified
using NIH ImageJ (National Institutes of Health, Bethesda, MD).

Immunofluorescent Staining, Confocal Imaging and Analysis

Cells were seeded on collagen IV-coated, 22 mm (diameter) round coverslips at
5,000 cells/coverslip and allowed to attach overnight. They were then starved in 1% serum
media for 24 hours. Cells stained for smooth muscle α-actin (Sigma-Aldrich, St. Louis, MO,
1:100), MRTF-A (H-140; Santa Cruz Biotechnology, Santa Cruz, CA, 1:50) and vinculinFITC (Sigma-Aldrich, St. Louis, MO, 1:200) were fixed with 4% paraformaldehyde in 0.1
M phosphate buffer for 10 min at room temperature after washing twice with PBS. Cells that
were used for Y397 pFAK (Millipore, Bedford, MA, 1:50) staining were fixed with an icecold 1:1 acetone-methanol (both from Fisher Scientific, Pittsburg, PA) solution at -20°C for
5 min after washing twice with PBS. Cells that were treated with 10ng/mL TGF-β1 were
incubated for another 72 hours in fresh 1% serum medium after the initial 24 hours of serum
starvation and fixed with 4% paraformaldehyde as described above. At the end of fixation,
coverslips were washed three more times with PBS and stored at 4°C until use.
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For staining, cells were first permeabilized for 10 min in 0.1% Triton X-100 (Fisher
Scientific, Pittsburgh, PA) in PBS. Then, coverslips were inverted for 1 hour over a drop of
blocking solution containing 5% donkey serum (Jackson ImmunoResearch Laboratories,
West Grove, PA) in PBS. Incubation with primary antibodies at their respective
concentrations was performed also by inverting the coverslips onto 50 µl drops of antibody
diluted in blocking solution and leaving them at 4°C overnight. Coverslips were washed
three times for 2 min each in PBS and fluorescein isothiocyanade (FITC)-conjugated
secondary antibody (Jackson ImmunoResearch Laboratories, West Grove, PA) diluted in
blocking solution was used for one hour at room temperature in the dark. Another three twominute washes were performed, and, if necessary, a final 30-minute incubation in 1:40
Texas Red phalloidin (Life Technologies, Grand Island, NY) in blocking solution was
performed at room temperature in the dark. After final three two-minute washes, coverslips
were air-dried for 5 min and mounted using Vectashield mounting media with DAPI (Vector
Laboratories, Burlingame, CA) and sealed with nail polish.
Images were taken from random fields of the coverslips using a confocal microscope
(Nikon A1, Nikon Instruments, Melville, NY) at constant settings for all coverslips in an
experiment. Images were analyzed using Nikon NIS Elements software. Pearson correlation
coefficients for colocalization of blue (DAPI) or green (MRTF-A) were calculated for at
least 20 cells per slide on at least 3 slides for each bar presented on the graph. Additionally,
MRTF-A nucleus/cytoplasm ratios were calculated by measuring the mean intensity of the
nuclear versus the cytoplasmic staining of cells (7 slides per genotype, 10-30 cells per slide).
Calculating the relative colocalization of phalloidin and SM α-actin was done as with
MRTF-A and DAPI by estimating the Pearson correlation coefficient. Focal adhesion size
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was estimated by measuring at least 30 randomly selected focal adhesions for at least 3
images per slide for at least 3 slides for each bar on the graph. Measurements were
performed by a blinded volunteer in order to avoid involuntary biasing of results.

SMC Proliferation Assays

Cell proliferation was measured by quantifying BrdU incorporation into the DNA of
cells. SMCs were plated on 96-well plates, coated with collagen IV, seeded at 5,000
cells/well and allowed to attach overnight in complete media. The cells were then starved in
1% serum media with or without inhibitors for 24 hours. BrdU reagent was added to the
wells 30 min after serum starvation/inhibitor treatment. The plates were then fixed and
quantified with an ELISA assay according to the manufacturer’s protocol (Millipore,
Bedford, MA). The inhibitors used include PF573228 (FAK inhibitor – Tocris Bioscience,
Ellisville, MO) at a 1µM concentration, 10µM Imatinib mesylate (Selleck Chemicals,
Houston TX), 20 µM LY294002 (PI3K inhibitor - Cell Signaling Technology, Danvers
MA), and 10 µM U0126 (MEK inhibitor – Sigma Aldrich, St. Louis, MO). Dimethyl
sulfoxide (DMSO; 0.6 uL per 2.5 mL media) was used as vehicle control.

F/G Actin Assays

The ratio of polymerized to unpolymerized actin was measured using an F/G actin
assay (Kit BK-037, Cytoskeleton, Denver, CO). Cells were seeded on 60 mm collagen IV –
coated dishes at 200,000 cells/dish and left in complete media to attach overnight. The next
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day cells were washed once in PBS and serum starved in 1% SmBM for 24 hours. At the
end of the 24 hours, cells were either treated with 10ng/ml TGF-β1 for 72 hours or directly
lysed for the assay according to manufacturer’s protocol. Briefly, cells were lysed, collected
into centrifuge tubes and sheared with a bent 26½ – gauge needle. Wildtype controls were
treated either with 10µM phalloidin (positive control) or with 10µM cytochalasin D
(negative control). Cells were spun down for 5 min at 376 x g, transferred into
ultracentrifuge tubes and spun in an ultracentrifuge (Optima TLX Ultracentrifuge, Rotor
TLA-110, Beckman Coulter, Brea, CA) for 1 hour at 126,000 x g and 37°C in a rotor that
was pre-warmed to 37°C for a minimum of 1 hour. Supernatant and pellet were then
separated and the pellet was resuspended in ice-cold lysis buffer with 10µM cytochalasin D
or F-actin destabilization buffer and sheared with 26½ - gauge needle every 15 min for one
hour on ice.
Sixteen microliters of each sample were then loaded on an SDS-PAGE gel and
processed for immunoblot analysis with α-SMA (Sigma- Aldrich, St. Louis, MO).

Actin Filament Breakdown Assay

Five thousands cells were seeded on collagen IV-coated coverslips and left to attach
for one hour before complete medium was added and the cells were incubated overnight.
Next, cells were serum-starved for 24 hours, at the end of which they were resuspended in
fresh 1% serum medium and treated with 10ng/ml TGF-β1 for 48 hours. At the end of the 48
hours, SMCs were treated with 0.5 µM Latrunculin A (Cayman Chemicals, Ann Arbor, MI)
for 0hr, 5 min, 10 min, 15 min or 1 hour. Coverslips were fixed with 4% paraformaldehyde
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as previously described, immunostained for smooth muscle α-actin and total actin
(phalloidin) and viewed under a Confocal microscope.

RhoA/Rac1 Activation Assays

Activation of RhoA and Rac1 were measured by G-LISA assays according to
manufacturer’s protocol (Kits BK-124/128, Cytoskeleton, Denver, CO). Briefly, cells were
seeded onto collagen-IV coated 60 mm dishes at 200,000 cells/ dish and were grown
overnight in complete SmBM at 37°C. SMCs were then serum starved in 1% SmBM for 24
hours, at the end of which they were treated with or without lypophosphatidic acid (LPA;
Sigma-Aldrich, St. Louis, MO) for 15 min for Rac1 activation. Cells were then washed with
ice-cold PBS, lysed in 120µl of lysis buffer with protease inhibitors in a 4°C room and snap
frozen after a 12 µL aliquot was taken out for protein quantification. Protein levels were
quantified for each sample using 10µL of the aliquot and 300 µL of the provided Precision
Red Protein Quantification Reagent at OD 600 nm. For both RhoA and Rac1 activation
assays, 0.3-0.5 µg of protein were used per well in a provided reaction plate for subsequent
G-LISA analysis. Reactions were performed in duplicate or triplicate.

Statistical Analysis

Student t-tests were used to compare samples from each genotype to wildtype for all
experiments. P-values were considered significant (*) when p<0.05, highly significant (**)
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at p<0.01 and (***) p<0.001. Error bars on each graph represent either the standard
deviation (s.d.) or 95% confidence intervals (C.I.), as indicated in the respective legends.
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Table1: Antibody Product and Dilution Information
Antibody

Company

IB

IF

α-tubulin

Cell Signaling Technology, Danvers, MA

1:500

---

α-smooth muscle actin

Sigma-Aldrich, St. Louis, MO

1:1,000

1:100

SM22α

Abcam, Cambridge MA

1:1,000

---

Calponin 1

Sigma-Aldrich, St. Louis, MO

1:1,000

---

SM-MHC

Biomedical Technologies Inc, Stoughton, MA

1:1,000

---

GAPDH

Fitzgerald Industries International, Acton, MA

1:20,000 ---

pAKT (Ser473)

Cell Signaling Technology, Danvers, MA

1:500

---

Total AKT

Cell Signaling Technology, Danvers, MA

1:1,000

---

pFAK

Millipore, Bedford, MA

1:500

1:25

Total FAK

Santa Cruz Biotechnology, Santa Cruz, CA

1:1,000

---

pPDGFRβ

Santa Cruz Biotechnology, Santa Cruz, CA

1:500

---

Total PDGFRβ

Cell Signaling Technology, Danvers, MA

1:1,000

---

Vinculin

Sigma-Aldrich, St. Louis, MO

---

1:200

MRTF-A (H140)

Santa Cruz Biotechnology, Santa Cruz, CA

---

1:50

p42/44 MAPK

Cell Signaling Technology, Danvers, MA

1:1,000

---

Phospho-p44/42 MAPK

Cell Signaling Technology, Danvers, MA

1:500

---

MRTF-A (C19)

Santa Cruz Biotechnology, Santa Cruz, CA

1:500

---

Jackson ImmunoResearch Laboratories, West

---

1:200

---

1:200

1:2,000

---

1:2,000

---

Primary antibodies:

Secondary Antibodies:
Mouse-FITC

Grove, PA
Rabbit-FITC

Jackson ImmunoResearch Laboratories, West
Grove, PA

Mouse HRP

Jackson ImmunoResearch Laboratories, West
Grove, PA

Rabbit HRP

Jackson ImmunoResearch Laboratories, West
Grove, PA
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CHAPTER THREE: Actin Filament Formation and Stability in Acta2+/+ R258C TG and
Acta2+/- R258C TG Mouse Aortic Smooth Muscle Cells
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Introduction

In order to confirm the importance of α-actin for the normal functioning of vascular
SMCs, we first characterized an Acta2 null mouse model. This model was first described by
Schildmeyer et al (2000), who found that the loss of α-actin did not affect the development
of the vasculature in these mice but led to decreased aortic contractility, as well as decreased
blood pressure. Further, these mice were described to have impaired milk ejection ability
(85-86), similar to MRTF-A deficient mice (24-25). Interestingly, compensatory expression
of skeletal actin was noted in the aortas of Acta2-/- mice (84).
Detailed study of the aortas of the Acta2-/- mice using echocardiography and
histology established that the Acta2 null mice develop significant aortic dilatations by 8
weeks of age (Fig. 3.1A), coupled with an increase in medial thickness, which reaches
significance at 1 year (Fig. 3.1B). These mice have increased density of SMCs in the aortic
wall at 4 weeks, which decreases as their aortic diameter progressively increases with age
(Fig. 3.1B). Further, Acta2-/- mice have increased numbers of elastic lamellae in their aortas
(Fig. 3.1B) and mild proteoglycan accumulation with age, in agreement with the mild aortic
disease phenotype (87). These findings are, unsurprisingly, more pronounced but similar to
our findings in the Acta2+/+ R258C TG and Acta2+/- R258C TG mice.
Assessment of the levels of expression of contractile genes and proteins in explanted
aortic Acta2-/- SMCs showed that these SMCs are highly differentiated by the classical
definition of increased expression of contractile markers (Fig.3.1C). While there were no
differences in total actin levels in the cells, there was a compensatory increase in γ-SM actin
levels in these cells. Immunofluorescent staining for MRTF-A and quantification of the ratio
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between the nuclear and cytoplasmic fraction indicated that MRTF-A is significantly more
nuclear in Acta2-/- SMCs (Fig. 3.1D, E). Thus, the loss of α-actin in these SMCs leads to
increase in γ-actin filaments, differential MRTF-A localization in the nucleus, expression of
high levels of contractile markers and, therefore, a differentiated phenotype despite the
decrease in whole aorta contractility (87). We wanted to test whether introducing the
R258C mutation in α-actin conferred a similar phenotype or, on the contrary, a less
differentiated phenotype as a result of filament disruption and MRTF sequestration in the
cytoplasm.

Figure 3.1: Aortic and Vascular Smooth Muscle Cell Phenotype of Acta2-/- Mice. A.
Acta2-/- mice have significantly larger aortic diameters starting at 8 weeks. From J. Cao, MD
PhD and colleagues (unpublished data) (87), with permission. B. Medial area in Acta2-/mice increased with age, while cell density decreases. Acta2-/- mice have significantly more
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elastic layers in their aortas. From J. Cao, MD PhD and colleagues (unpublished data) (87),
with permission. C. SMCs from the ascending aorta of Acta2-/- mice express contractile
markers at significantly greater levels compared to wildtype. D. MRTF-A is predominantly
localized in the nucleus of Acta2-/- SMCs. E. Quantification shows that nuclear MRTF-A
localization in Acta2-/- SMCs is significantly greater than in wildtype SMCs. *p<0.05; error
bars represent ±standard error of the mean (s.e.m.) C,D,E from C. Papke, PhD and
colleagues (unpublished data) (88), with permission.
Results

RNA from explanted aortic SMCs was used to generate cDNA for quantitative realtime PCR (Fig. 3.2A). All results are normalized to Gapdh and presented as fold change
compared to wildtype (which is set to 1). Smooth muscle cells from Acta2+/+ R258C TG mice
show a significant increase in expression of all smooth muscle contractile genes. Acta2+/R258C TG

SMCs, on the other hand, only show a significant increase in expression of smooth

muscle myosin heavy-chain (Myh11) and calponin 1 (Cnn1) genes, while Acta2 and SM22α,
another SMC-specific contractile marker, levels are unchanged. Acta2+/- SMCs show no
significant difference in gene expression compared to wildtype SMCs for any of the
contractile markers. These SMCs also exhibited a lot of variability between different
experimental repeats, making them a less reliable control. Thus, while Acta2+/+

R258C TG

SMCs showed a consistent and significant increase in contractile gene expression, Acta2+/R258C TG

SMCs only express significantly more Cnn1 and Myh11 mRNA and have expression

similar to wildtype cells for other contractile genes. The observed increase in Myh11 in both
transgenic lines confirms that the explanted cells are in fact SMCs and not fibroblasts, as
differentiated fibroblasts express most smooth muscle contractile genes at comparable levels
except for Myh11 (14).
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Contractile protein levels as shown by a quantified Western blot in Fig. 3.2B
(quantification in Appendix 3A) indicate that the increased contractile gene expression in
Acta2+/+ R258C TG SMCs is matched by a similar increase in contractile protein expression. All
proteins but myosin heavy chain (SM-MHC) were expressed at higher levels compared to
the wildtype, and myosin levels were unchanged. However, both Acta2+/- and Acta2+/- R258C
TG

SMCs express lower levels of α-actin and SM22α compared to wildtype cells. Calponin 1

was more strongly expressed in Acta2+/- R258C TG compared to wildtype cells, and SM-MHC
protein levels were unchanged. Acta2+/- SMCs had comparable expression levels to the
Acta2+/- R258C TG (Appendix 3A)

Figure 3.2: Contractile Gene and Protein Expression in Wildtype (WT), Acta2+/+
R258C TG
, Acta2+/- and Acta2+/- R258C TG SMCs. A. Quantitative real-time PCR data for the
expression of the contractile genes Acta2, Myh11, Cnn1 and SM22α in all four genotypes.
Wildtype is set to 1 for each assay and gene expression in the other genotypes is
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presented as a fold difference from the wildtype. All results are normalized to Gapdh. *
p<0.05, ** p<0.01. Error bars are ±standard deviation (s.d.) B. Contractile protein
expression, as shown by Western blot. SM-MHC = smooth muscle myosin heavy chain.
SM α-actin = smooth muscle-specific α-actin.
Next, we assessed whether α-actin could incorporate into actin filaments by staining
smooth muscle cells with α-smooth muscle actin antibody and all filamentous actin with
Texas Red phalloidin (Fig. 3.3A). Similar to wildtype cells, Acta2+/+ R258C TG cells appeared
to form proper filaments without any visible pools of unpolymerized α-actin (Fig. 3.3A);
there was also no significant difference in the colocalization of red and green in these cells
compared to wildtype (Fig. 3.3B). Acta2+/- R258C TG and Acta2+/- SMCs, however, had larger
pools of unpolymerized α-actin (Fig. 3.3A); hence, α-actin colocalized significantly less
with phalloidin in these cells (Fig. 3.3B). In order to quantitatively assess the relative
amount of polymerized to unpolymerized α-actin in each cell type, we performed an F/G
actin assay on SMCs that were serum-starved for 24 hours (Fig. 3.3C). As expected based
on the immunofluorescence results in Fig. 3.3A, all of the α-actin in Acta2+/- R258C TG and
Acta2+/- SMCs was unpolymerized (Fig. 3.3C, Appendix 3B). Interestingly, the
unpolymerized fraction in Acta2+/+ R258C SMCs based on the F/G actin assay was also much
larger than the polymerized (Fig. 3.3C Appendix 3B), which differs from the observations
by immunofluorescence and indicates a potential instability in the filaments.
In order to further assess the discrepancy in the results for Acta2+/+ R258C TG SMCs’
ability to form actin filaments, we performed an F/G actin assay after lysing and then
treating the SMCs with phalloidin in order to stabilize the existing filaments (Fig. 3.3D). We
predicted that performing an F/G actin assay on the pre-treated lysates would allow to better
replicate the results from the immunofluorescent staining in Fig. 3.3A. Indeed, treating cells
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with phalloidin increased the polymerized fraction in all genotypes, with a small
unpolymerized fraction remaining only in Acta2+/+ R258C TG SMCs, which is also the genotype
with the largest amount of total α-actin, too (Appendix 3C). This indicates that in all
genotypes, mutant α-actin is able to incorporate in filaments, but phalloidin treatment or
other stimulus is required in order for polymerization to happen. Together, the F/G actin
assays indicate that at baseline, the Acta2+/+ R258C TG SMCs form filaments, which, however,
are more prone to breakdown as the unpolymerized actin fraction remains greater than the
polymerized.

56

Figure 3.3: Alpha-actin Polymerization in Wildtype (WT), Acta2+/+ R258C TG, Acta2+/- and
Acta2+/- R258C TG SMCs at Baseline. A. Immunofluorescent staining for SM α-actin (green),
F-actin (phalloidin, red), and nucleus with DAPI after 24 hours of serum starvation. B.
Quantification of the colocalization of α-SMA and phalloidin, presented by an estimate of
the Pearson’s correlation coefficient. Results shown are pooled from three independent
experiments *** p<0.001. Error bars are ± 95% confidence interval (C.I.) C. F/G actin assay
for all four genotypes. Positive control = wildtype cells after phalloidin treatment. Negative
control = wildtype cells after cytochalasin D treatment. U= unpolymerized, P=polymerized.
D. F/G actin assay for cells with or without phalloidin treatment.
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Next, we treated the SMCs with TGF-β1 for 72 hours to reach a more differentiated
phenotype (89) and stained for α-SMA and filamentous actin. All SMCs showed at least
partial incorporation of α-actin into filaments (Fig. 3.4A). Acta2+/+ R258C TG SMCs appeared
to incorporate all of their α-actin into filaments, although the filaments often appeared
thinner, less organized and more fragile than the wildtype filaments. Acta2+/- R258C TG and
Acta2+/- SMCs formed few filaments, and they also had pools of unpolymerized actin,
indicating that there might be a critical amount of actin required by SMCs in order for
polymerization and incorporation into filaments to occur.
When an F/G actin assay was performed on cells treated with TGF-β1 and incubated
for 72 hours, we saw that while there was a polymerized fraction of α-actin for all
genotypes, the unpolymerized fraction was much greater for all three non-wildtype
genotypes compared to the wildtype (Fig 3.4B, Appendix 3D), supporting the prediction
that stability of the filaments is impaired as a result of the mutation in α-actin. Taken
together, these data show that the non-wildtype SMCs are able to form filaments but require
a stimulus, such as TGF-β1 or phalloidin, in order to achieve that.
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Figure 3.4: Actin Polymerization After 72 Hours of TGF-β1 Treatment. A.
Immunofluorescent staining after 72 hours of TGF-β1 treatment for α-SMA (green) and
total filamentous actin (phalloidin, red). Nuclei were stained with DAPI (blue). B. F/G
actin assay after 72 hours of TGF-β1 treatment. Positive ctrl= wildtype cells treated with
phalloidin. U=unpolymerized. P=polymerized
In order to test if the Acta2+/+ R258C TG filaments break down more quickly than the
wildtype filaments as a result of the R258C mutation, we treated coverslips with TGF-β1 for
48 hours, followed by treatment with 0.5 µM Latrunculin A for 0, 5, 10, 15 min and 1 hour.
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Immunofluorescence for SM α-actin and phalloidin showed that wildtype SMC filaments
have begun to fall apart by 5 min and are almost completely broken down by 15 min of
treatment, and missing by 1 hour. In contrast, the Acta2+/+ R258C TG SMCs appear to have still
some polymerized filaments after one hour of Latrunculin A treatment, and a delayed
response at all earlier timepoints (Fig. 3.5). As the rate of polymerization during actin
treadmilling is the same as the rate of depolymerization, our findings suggest that Acta2+/+
R258C TG

SMCs surprisingly have less dynamic filaments compared to wildtype SMCs. This

finding may be important under conditions of stress, where the ability to quickly respond
and assemble new contractile filaments to withstand force across the cell is highly
important.
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Figure 3.5: Actin Filament Breakdown After Latrunculin A Treatment. Wildtype cells
show disrupted filaments as early as 5 min after treatment with 0.5 µM Latrunculin A and
complete filament loss by 1 hour, while Acta2+/+ R258C TG SMCs have partial filaments even 1
hour post- treatment. Green = α-SM actin.
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We next assessed the cellular localization of MRTF-A under the hypothesis that
MRTF-A localization would reflect the level of contractile gene expression and the
proportion of unpolymerized actin fraction observed for each genotype. Immunofluorescent
staining for MRTF-A and the nucleus (with DAPI, Fig.3.6A) and quantification of the ratio
of nuclear versus cytoplasmic MRTF-A signal using two independent methods indicated
differences in the cellular localization of MRTF-A among the four genotypes (Fig. 3.6B),
which matched the gene expression data for these cells (Fig. 3.2A). Acta2+/+ R258C TG SMCs
showed increased colocalization of MRTF-A with the nucleus, which matched the observed
increased contractile gene expression and indicated that sufficient filament formation
occured in these SMCs to allow MRTF-A translocation. Acta2+/-

R258C TG

SMCs showed

significantly less nuclear localization of MRTF-A, in accordance with the observed large
unpolymerized cytoplasmic actin fractions and the lower expression of contractile genes
compared to Acta2+/+

R258C TG

SMCs. Finally, colocalization data for Acta2+/- SMCs

indicated that, in these cells, a similar proportion of MRTF-A is found in the nucleus when
compared to wildtype cells. This also matches contractile gene expression data for the
heterozygous cells, which showed no significant difference in the contractile gene
expression when compared to wildtype cells. Interestingly, we also found increased
expression of total MRTF-A in all three non-wildtype cell lines (Fig. 3.6C, Appendix 3E).
Finally, expression of c-fos was significantly increased in the Acta2+/- R258C TG SMCs, in line
with increased cytoplasmic MRTF-A localization in these cells (Fig. 3.6D).
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Figure 3.6: MRTF-A Localization and Expression in Wildtype (WT), Acta2+/+ R258C TG,
Acta2+/- and Acta2+/- R258C TG SMCs A. Staining with MRTF-A (green) and DAPI (blue)
reveals differential localization of MRTF-A in the four genotypes B. Nuclear localization of

63

MRTF-A, presented by the Pearson correlation coefficient for blue and green (top) and as a
ratio of nuclear/cytoplasmic intensity of staining ratio (bottom) indicates significantly
greater colocalization of MRTF-A with the nucleus in Acta2+/+ R258C TG SMCs, and
significantly less colocalization of MRTF-A with DAPI in Acta2+/- R258C TG SMCs. There is
no significant difference between wildtype cells and Acta2+/- R258C TG SMCs. The results
shown are pooled from three (top) or two (bottom) independent experiments. *p<0.05
***p<0.001. Error bars± 95% C.I. C. MRTF-A expression in the Acta2+/+ R258C TG SMCs and
the Acta2+/- SMCs is increased compared to WT SMCs. D. C-fos expression is increased
only in Acta2+/- R258C TG SMCs. *p<0.05. Error bars ± s.d.
So far we have been able to show that mouse smooth muscle cells expressing an
Acta2 R258C mutant transgene in an Acta2+/+ or Acta2+/- background exhibit a change in
contractile gene and protein expression, actin filament stability, and MRTF-A localization.
The Acta2+/+

R258C TG

SMCs are able to form filaments, which allows for MRTF-A to

translocate to the nucleus and potentially drives the expression of contractile markers. Thus,
Acta2+/+

R258C TG

SMCs are differentiated by the classical definition of showing increased

expression of contractile markers. Acta2+/- SMCs, on the other hand, have pools of
unpolymerized α-actin and limited filament formation, and even 3 days after TGF-β1
treatment, they still have only about 50% of α-actin incorporated in filaments. MRTF-A
localization in the Acta2+/- R258C

TG

SMCs is more cytoplasmic than in wildtype cells, and

together with the modest increases in contractile gene expression and the lower contractile
protein expression, it points to a less differentiated phenotype due to impaired filament
formation.

Finally, all three non-wildtype genotypes require an external stimulus to

efficiently incorporate monomeric actin into filaments, and Acta2+/+ R258C TG SMCs appear to
have more brittle but less dynamic filaments compared to wildtype SMCs.
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CHAPTER FOUR: Focal Adhesion Alterations in Acta2+/+ R258C TG and Acta2+/- R258C TG
Mouse Aortic Smooth Muscle Cells
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Introduction

As explained in chapter one, focal adhesions (FAs) are clusters of proteins around
integrin receptors at the plasma membrane, which connect the cytoskeleton and actomyosin
contractile unit to the extracellular matrix. FAs are signal- and mechanotransducers, and
their maturation in fibroblasts has been shown to depend on both actin polymerization and
on myosin motor function (43-44). We studied the importance of α-actin and myosin
function for the maturation of focal adhesions using SMCs from a mouse model that has
decreased myosin function (48), as well as in SMCs from mice lacking α-actin (88).
Interestingly, we found differences in the focal adhesion alterations due to the defect in
myosin motor function and the ones due to loss of α-actin.
In SMCs from the Myh11R247C/R247C mice, which have significantly impaired myosin
function, we found that compared to wildtype SMCs, the Myh11R247C/R247C SMCs had
smaller focal adhesions as determined by staining for vinculin and activated focal adhesion
kinase (FAK), coupled with increased Rac1 activation and decreased RhoA activation.
These cells were also de-differentiated; activating RhoA using the bacterial endotoxin CN03
was able to restore the differentiated phenotype. Further, increased proliferation in these
SMCs was attenuated by blocking FAK (48). This study indicated the key role that focal
adhesion maturity and composition plays in regulating the SMC phenotype in response to
the cell’s contractile unit activity.
Focal adhesion maturation was also determined in SMCs from the α-actin deficient
mice. Analysis of focal adhesion size, number and localization using total internal reflection
fluorescent (TIRF) microscopy after immunostaining revealed dramatic differences in the

66

size, number and localization of focal adhesions in Acta2-/- SMCs. Compared to wildtype
SMCs, Acta2-/- SMCs have fewer focal adhesions, localized exclusively at the cell periphery
rather than throughout the cell (Fig. 4.1A,B). Further, the Acta2-/- SMC focal adhesions are
significantly larger in size as compared by both vinculin and pFAK staining (Fig. 4.1B).
Finally, while RhoA activation was not changed, Rac1 was significantly more activated
(Fig. 4.1C), consistent with less mature focal adhesions (88). Together, these data indicate
that loss of α-actin leads to a major reorganization and alteration of focal adhesions in these
SMCs, but that the exact changes are profoundly different compared to those in mice with a
defect in myosin motor function.
Given these findings, we hypothesized that FAs will also be altered in Acta2+/+ R258C
TG

and Acta2+/-

R258C TG

SMCs as a result of the impaired actin filament formation and

stability.

Figure 4.1: Focal Adhesion (FA) Alterations in Acta2-/- SMCs. A. Total Internal
Reflection Fluorescent (TIRF) microscopy images of pFAK- and vinculin-stained wildtype
and Acta2-/- SMCs. B. Quantification of the intensity and number of FAs in wildtype and
Acta2-/- SMCs. Ratio = ratio of protein area to total cell area. C. Rac1 is more activated in
Acta2-/- compared to wildtype SMCs; Quantified by G-LISA. *p< 0.05. Error bars ± s.d.
From C. Papke, PhD and colleagues (unpublished data) (88), with permission.
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Results

Smooth muscle cells from all four genotypes were first immunostained with a
vinculin antibody and examined under a laser confocal microscope (Fig. 4.2A).
Quantification of the focal adhesion size as assessed by the vinculin staining indicated that
Acta2+/+

R258C TG

, Acta2+/- and Acta2+/-

R258C TG

SMCs all had significantly larger focal

adhesions compared to wildtype cells. Importantly, the focal adhesions of Acta2+/- R258C TG
SMCs were also significantly larger than both the Acta2+/- and the Acta2+/+ R258C TG focal
adhesions (Fig. 4.2B). Further, compared to the wildtype SMCs, Acta2+/+

R258C TG

and

Acta2+/- R258C TG SMCs had fewer and more peripherally localized focal adhesions, similar to
the ones in the Acta2-/- SMCs.
The observed increase in focal adhesion size in non-transgenic SMCs was replicated
when the focal adhesions were quantified by immunofluorescent staining for activated FAK
(pFAK; Fig. 4.2A,B). Additionally, the differences between the Acta2+/+ R258C TG, Acta2+/and Acta2+/- R258C TG SMCs were all highly significant, suggesting a very distinct pattern of
FAK activation based on the genetic alteration (Fig. 4.2A,B). These observations were
confirmed by Western blot as well – while the Acta2+/+

R258C TG

had similar levels of

activated FAK compared to the wildtype cells, both the Acta2+/- and the Acta2+/-

R258C TG

SMCs had more activated FAK (Fig. 4.2C). The ratio of pFAK/FAK was elevated for all
non-wildtype SMCs, and consistently highest in the Acta2+/- R258C TG SMCs (Appendix 3F).
Akt, a common downstream target of activated FAK, was significantly less activated in the
Acta2+/+ R258C TG and the Acta2+/- SMCs, but comparable to wildtype in Acta2+/- R258C TG. A
comparison of the ratios of pAkt/Akt for all four genotypes confirmed decreased Akt
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activation in the non-wildtype SMCs (Fig. 4.2D, Appendix 3F). These data suggest that
there are differences in FAK activation, and that Akt is not the major downstream pathway
activated by FAK in these SMCs.
Given that the size and arrangement of the focal adhesions in the Acta2+/+ R258C TG
and the Acta2+/-

R258C TG

SMCs resemble the ones from SMCs lacking α-actin, we tested

whether the transgenic SMCs also had more Rac1 activation. Consistent with previous
findings and the expectation that focal adhesions are immature, we found that in the
Acta2+/+

R258C TG

SMCs Rac1 was significantly more activated, but RhoA remained

unchanged (Fig. 4.2D). Interestingly, we saw a significant decrease in the activation of Rac1
in the Acta2+/- SMCs and a similar but even more dramatic decrease in the Acta2+/- R258C TG
SMCs. RhoA activation was unchanged in the Acta2+/- SMCs but significantly lower in the
Acta2+/- R258C TG cells (Fig. 4.2D).
Taken together, data indicate that both transgenic cells lines have alterations in their
focal adhesion composition and size. Acta2+/+

R258C TG

SMCs have larger focal adhesions,

which contain more activated FAK and greater Rac1 activation. Acta2+/- R258C TG SMCs also
have significantly larger focal adhesions as quantified by vinculin and pFAK staining, as
well as even higher levels of activated FAK as quantified by Western blot. However, Rac1 is
decreased in these SMCs compared to wildtype cells, similar to Acta2+/- SMCs.
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Figure 4.2: Focal Adhesions Are Altered in Acta2+/+ R258C TG and Acta2+/- R258C TG SMCs.
A. Immunofluorescent staining for vinculin (green), total filamentous actin (phalloidin, red)
and nucleus (DAPI, blue), or pFAK (green) and nucleus (DAPI, blue). B. Quantification of
focal adhesion size in Acta2+/+ R258C TG and Acta2+/-R258C TG SMCs indicates that focal
adhesions are significantly larger in these SMCs compared to the wildtype. Acta2+/- SMCs
are only significantly larger than wildtype SMCs when size is determined by pFAK staining.
Results are pooled from three independent experiments for vinculin and two for pFAK.
*p<0.05, **p<0.01, *** p<0.001. Error bars ± 95% CI. C. Western blot showing increased
activation of FAK in all three non-wildtype genotypes. Akt activation, however, is lower
compared to the wildtype for all of them. D. G-LISA assays for RhoA and Rac1 activation
show that there is a significant decrease in RhoA activation in Acta2+/- R258C TG SMCs but no
change in the others compared to wildtype. Rac1 is significantly more activated in Acta2+/+
R258C TG
SMCs compared to the wildtype in unstimulated and LPA-stimulated cells, and
significantly less activated in Acta2+/- R258C TG SMCs under both conditions and in Acta2+/SMCs after LPA stimulation. RhoA activation is pooled from 3 experiments, Rac1 is a
representative experiment (one of three repeats) *p<0.05, **p<0.01. ***p<0.001. Error bars
± s.d.
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CHAPTER FIVE: Proliferation in Acta2+/+ R258C TG and Acta2+/- R258C TG Mouse Aortic
Smooth Muscle Cells
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Introduction

Increased proliferation is the hallmark of dedifferentiated smooth muscle cells.
Explanted SMCs and dermal fibroblast cells from patients with mutations in ACTA2 and
MYH11 show increased proliferation (Fig. 1.5B) (17; 68; 70). These patients also have a
high occurrence of vascular occlusive diseases in a number of smaller arteries, possibly due
to increased SMC proliferation.
The proliferative, occlusive vascular pathology observed in humans is retained the
Acta2-/- mice in vivo and in culture. Aortic SMCs explanted from the ascending aortas of the
knockout mice proliferate more in culture compared to wildtype SMCs (Fig.5.1A). When
we performed carotid artery ligations to assess the response to vascular injury in the Acta2-/mice, we unsurprisingly found that the carotid arteries of these mice were almost completely
occluded 21 days post-injury (Fig. 5.1B,C). The abnormal and significant increase in
neointima formation confirmed a pathologic proliferative response of these SMCs in vitro
and in vivo (88).
In trying to identify the mechanism by which a defect in contractile properties leads
to increased proliferation, we assessed the contribution of the impaired focal adhesion
maturation resulting from the loss of α-actin to increased proliferation in the Acta2-/- SMCs.
Work in different types of cancer has focused on the role of FAK in proliferation (90-92),
and more recently a role for FAK was established in cell proliferation in human lung
epithelial cells under conditions of continuous stretch and stress (93), which bear
resemblance to the conditions in the vasculature, too. Thus, we chose to determine whether
the increased activation of FAK was at least in part responsible for increased proliferation,
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and found that using a FAK-specific inhibitor, we were in fact fully able to block
proliferation (Fig. 5.1C, D) (88).
In cancer, FAK has been shown to interact with growth factor receptors, and this
cross-talk contributes to increased tumor proliferation (94-96). Therefore, we assessed if
there is any abnormal growth factor involvement in the Acta2-/- SMCs as well. There are
several growth factor receptors in SMCs that play key roles in modifying the smooth muscle
cell phenotype, but the most likely candidate for driving proliferation in the Acta2-/- SMCs,
the platelet-derived growth factor receptor beta (PDGFRβ), was studied. PDGFRβ is a
potent activator of SMC proliferation and migration and is highly important in the
development of the vasculature, as well as in response to injury when SMCs switch back to
a dedifferentiated phenotype (97-99). Indeed, PDGFRβ had increased expression at the
mRNA level in the Acta2-/- SMCs (Fig. 5.1F). There was more total PDGFRβ protein as
well as more activated PDGFRβ, as assessed by phosphorylation of tyrosine 1021 in the αactin-deficient SMCs, but the ratio of total to activated PDGFRβ was unchanged (Fig. 5.1F)
(88). Importantly, treating the SMCs with the tyrosine kinase inhibitor imatinib mesylate, an
FDA-approved cancer drug (100), was able to decrease proliferation in the Acta2-/- SMCs to
wildtype levels by decreasing PDGFRβ activation (Fig. 5.1G,H;) (88). Imatinib treatment
has been shown to be effective in treating pulmonary arterial hypertension (101-102). It has
also been shown to reduce excessive neointima formation after carotid artery ligation in a
neurofibromatosis mouse model, which developed occlusive vascular disease (103), and it
also prevented excessive neotintima formation in Acta2-/- mice (Fig. 5.1I) (88), highlighting
the potential relevance of this drug in treating patients with occlusive vascular diseases due
to mutations in ACTA2.
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Figure 5.1: Increased SMC Proliferation in Acta2-/- Mice in Vivo and in Culture Is
Driven by FAK and PDGFRβ Activation and Can Be Attenuated by Inhibition of FAK
in Culture and by Imatinib Both in Culture and in Vivo. A. Proliferation in Acta2-/SMCs is significantly increased compared to wildtype SMCs. *p<0.05. Error bars ± s.d. B.
Acta2-/- mice have increased neointima formation 21 days after carotid artery ligation. C.
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Quantification of carotid ligation response confirms significant increase in neointima
formation in Acta2-/- mice. *p<0.05. Error bars ± s.e.m. D. Western blot showing increased
Y397 pFAK expression in Acta2-/- SMCs. E. Two different FAK inhibitors are able to
attenuate proliferation in Acta2-/- SMCs. *p<0.05. Error bars ± s.d. F. Increased Pdgfrb gene
expression and total and activated PDGFRβ expression in Acta2-/- SMCs. Error bars ± s.d.
G. Imatinib treatment attenuates proliferation in Acta2-/- SMCs. *p<0.05. Error bars ± s.d.
H. Imatinib, but not PF573228 (PF-228; FAK inhibitor), can partially reduce PDGFRβ
activation. I. Treating carotid artery ligation site with imatinib post-ligation prevents
pathologic neointima formation in Acta2-/- mice. *p<0.05 Figures from C. Papke, PhD and
colleagues (unpublished work), with permission.
We performed carotid artery ligation on the Acta2+/+

R258C TG

and Acta2+/-

R258C TG

mice in order to assess their response to injury, and found that 21 days post-surgery, the
Acta2+/+ R258C TG mice did not have significantly greater neointima formation compared to
wildtype mice, but the Acta2+/- R258C TG mice did, as well as significantly thicker media and a
significantly larger media/intima ratio (Fig. 1.9A, B) (81). Therefore, we wanted to assess
whether proliferation was increased in the smooth muscle cells of the Acta2+/+ R258C TG and
Acta2+/- R258C TG mice, and whether the pathways found to drive the proliferation in Acta2-/SMCs are also implicated here. Given the many parallels between the Acta2

R258C TG

and

Acta2-/- models in vivo and in culture, we hypothesized that SMCs with the R258C mutation
will proliferate more, and that the pathways driving this response will involve FAK
activation and the PDGFRβ.

Results

In order to assess proliferation, we performed a BrdU ELISA assay on our SMCs.
Data indicate that both Acta2+/+

R258C TG

and Acta2+/- R258C TG SMCs proliferate more than

wildtype SMCs in culture, with the Acta2+/-

R258C TG

SMCs proliferating even more than
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Acta2+/+

R258C TG

SMCs (Fig. 5.2A). Acta2+/- SMCs showed such dramatic variation in

proliferation between different runs of the assay under identical conditions that we chose not
to include them in our comparison of proliferative ability.
We first wanted to test the role of FAK in driving the increased proliferation. We
already showed that FAK is not activating the PI3K-Akt pathway, a survival pathway, which
suggests that FAK may instead be differentially activating proliferative pathways. In order
to test whether FAK activation was driving the increased proliferation in the Acta2+/+ R258C
TG

and Acta2+/- R258C TG SMCs, we treated the SMCs with 1µM PF573228, a highly specific

FAK inhibitor. Data presented in Fig. 5.2B indicates that treating SMCs with the PF573228
was able to partially decrease the proliferation in Acta2+/- R258C TG SMCs, but not in Acta2+/+
R258C TG

SMCs, consistent with differences in pFAK levels in these SMCs. Further, when we

used the PI3K inhibitor LY294002 we found a paradoxical increase in proliferation (Fig.
5.2C), consistent with compensatory activation of MAPK pathways in the LY294002treated SMCs.
Next, we wanted to assess the potential role of the PDGFRβ in proliferation. We
determined mRNA expression and protein levels using quantitative real-time PCR and
Western blot and found an increase in the expression of the Pdgfrb gene only in the Acta2+/+
R258C TG

SMCs (Fig. 5.2D) and of phosphorylated PDGFRβ in the Acta2+/+

Acta2+/- SMCs, but not in the Acta2+/-

R258C TG

R258C TG

and

SMCs (Fig. 5.2D, Appendix 3H).

Interestingly, ERK1/2, which is downstream of the PDGFRβ, as well as many other
proliferative pathways, was also only activated in the Acta2+/+

R258C TG

SMCs (Fig. 5.2E,

Appendix 3G). We tested whether a MEK inhibitor, U0126, could block proliferation in the
Acta2+/+ R258C TG SMCs, and found, unsurprisingly, that to be the case (Fig. 5.2F). However,
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when we tested whether imatinib could block proliferation in all cell lines, we found only a
partial effect on the Acta2+/+ R258C TG SMCs but a much stronger effect in the Acta2+/- R258C TG
SMCs, in which imatinib brought proliferation down to wildtype levels (Fig. 5.2G).

Figure 5.2: Proliferation Is Increased in Acta2+/+ R258C TG and Acta2+/- R258C TG SMCs and
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Can Be Partially Attenuated by Imatinib and PF573228. A. Both Acta2+/+ R258C TG and
Acta2+/- R258C TG SMCs proliferate more than wildtype SMCs. B. Treating SMCs with 1µM
PF573228 (FAK inhibitor) significantly attenuates proliferation only in the Acta2+/- R258C TG
SMCs. *p<0.05 ***p<0.001. C. Treating cells with 20µM LY294002 causes an increase in
proliferation in all cell lines, including wildtype. D. Pdgfrb expression is only borderline
significantly increased in Acta2+/+ R258C TG SMCs, but not in any other cell line. The Acta2+/+
R258C TG
SMCs also have more activated PDGFRβ, as well as total receptor. E.
Phosphorylated ERK is only elevated slightly in Acta2+/+ R258C TG SMCs, and it is lower than
the wildtype in Acta2+/- and Acta2+/- R258C TG SMCs. F. Treatment with 10µM U0126, a MEK
inhibitor, can completely block proliferation in Acta2+/+ R258C TG SMCs. G. 10µM Imatinib
treatment partially blocks proliferation in Acta2+/+ R258C TG SMCs and completely in Acta2+/R258C TG
SMCs. *p<0.05, **p<0.01, ***p<0.001.All error bars ±s.d.
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CHAPTER SIX: Discussion
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An overarching goal of our lab is to understand how mutations in contractile and
other proteins can cause such profound and devastating vascular diseases in patients so that
we can improve clinical management and treatment for these patients. We sought to
characterize the aortic smooth muscle cell phenotype of transgenic mice carrying the Acta2
R258C mutation in order to determine whether the mutation had a dominant negative effect
and whether decreasing the ratio of wildtype to mutant actin would increase the severity of
the phenotype. Our in vivo data indicating decreased aortic contractility in the Acta2+/+ R258C
TG

mice and increased neotintima formation in response to carotid injury in the Acta2+/- R258C

TG

mice point towards a dual effect of the mutation – impaired contractile properties and

increased proliferation. Further, we observed an increase in both neotintima formation postinjury and in aortic disease when we introduced mutant α-actin in mice with an Acta2+/background compared to the Acta2+/+ R258C TG mice, which suggested that the Acta2+/- R258C TG
mice develop vascular pathology similar to that in patients who are heterozygous for the
ACTA2 R258C mutation. These findings led us to hypothesize that the phenotype of SMCs
explanted from these two mutant mouse models will similarly become more severe when the
ratio of wildtype to mutant α-actin is decreased. Data presented here confirms this
hypothesis but also highlights the dramatic differences in the pathways activated in the
Acta2+/+ R258C TG versus Acta2+/- R258C TG SMCs caused by the decrease in wildtype to mutant
α-actin content. Finally, these findings suggest a key role of α-actin in modulating SMC
phenotype and function.
In assessing the ability of the Acta2+/+ R258C TG SMCs and Acta2+/- R258C TG SMCs to
form α-actin filaments, we found some interesting differences. Immunofluorescent staining
revealed that the Acta2+/+

R258C TG

SMCs formed actin filaments but the Acta2+/-

R258C TG
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SMCs had large pools of unpolymerized actin and few filaments. Even 72 hours post-TGFβ1 treatment, most of the actin in the Acta2+/-

R258C TG

remained in monomeric form.

Interestingly, when we performed an F/G actin assay, we found that both cell lines lacked
pelleted filaments, suggesting that the Acta2+/+ R258C TG filaments visualized in the cells are
unstable when stressed. Treating the cells with phalloidin prior to centrifugation effectively
stabilized the polymerized actin in Acta2+/+ R258C TG SMCs, allowing it to be pelleted. This
result indicates that the cells are in fact able to form filaments, as observed with
immunofluorescence, but these filaments cannot withstand the shearing and agitation
required in preparation for the F/G actin assay. Interestingly, the Acta2+/- R258C TG SMCs also
produced a pellet after treatment with phalloidin. Phalloidin addition has been known to
reduce the critical concentration required for actin polymerization to occur in vitro, in
addition to accelerating new filament formation by promoting actin nucleation (104). Thus,
our finding in the Acta2+/-

R258C TG

SMCs suggested that phalloidin may cause α-actin to

polymerize more effectively and/or stabilize the filaments that are formed.
Concomitant with an increase in the percentage of cells staining positively for actin
filaments in both the Acta2+/+

R258C TG

SMCs and, to a lesser extent, the Acta2+/-

R258C TG

SMCs, at 72 hours post-TGF-β1 treatment, about 50% of actin appeared in the polymerized
fraction of both cell types. Therefore, growth factor stimulation induced a more
differentiated phenotype and more stable filaments in these SMCs. This finding may also be
relevant in vivo, where stimulation by the extracellular matrix, TGF-β1, biomechanical
forces, or other factors may promote similar α-actin filament stability in the SMCs, which
could potentially preserve the integrity of the arterial wall resulting in less vascular disease
than what would be expected based on the cellular defects.
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The findings in the Acta2+/-

R258C TG

SMCs were also seen in part in the Acta2+/-

SMCs. Both SMCs showed few filaments by immunofluorescence both after 24 hours of
serum starvation and after 72 hours of TGF-β1 treatment, suggesting that the wildtype αactin haploinsufficiency contributes to decreased actin polymerization, which further
supports the hypothesis that actin does not reach a critical concentration in these SMCs and
hence polymerization is difficult to initiate. The Acta2+/- SMCs also responded to phalloidin
treatment prior to performing an F/G actin assay, as we observed pelleting of almost the all
α-actin, as well as to TGF-β1 treatment which allowed for approximately 50%
polymerization to occur, again suggesting that the inherent ability of these, like the Acta2+/R258C TG

, SMCs to polymerize is not impaired.
While haploinsufficiency of wildtype actin is alone sufficient to inhibit actin

polymerization based on the findings by F/G actin assay and immunofluorescent staining,
there is evidence for additional effects of the R258C mutation on actin polymerization in the
Acta2+/- R258C TG SMCs. Even though it is difficult to separate the effects of the loss of the
wildtype allele and the mutant transgene insertion on actin filament formation, it is notable
that the Acta2+/-

R258C TG

SMCs express similar levels of total α-actin compared to the

Acta2+/- SMCs, and yet α-actin integrates into filaments less well than in the heterozygous
SMCs (Fig. 3.3A, B). This observation is supported by preliminary in vitro studies using
human α-actin expressed in a bacculovirus system, which suggest that the critical
concentration of α-actin R258C mutant monomers required for polymerization to occur is
higher than in the wildtype, and thus more protein is required for filaments to begin to form
(Kathleen Trybus, PhD, and colleagues, personal communication). This subtle difference
between the two heterozygous genotypes is masked when the cells are treated with TGF-β1
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because of increased expression of Acta2 and other contractile proteins in both cell lines.
Further, downstream changes resulting from the defect in actin filament formation in the
Acta2+/-

R258C TG

and Acta2-/- SMCs, such as MRTF-A localization, focal adhesion size or

proliferation ability, were different in these two cell lines. Therefore, we conclude that the
Acta2+/- R258C TG SMC phenotype is unique and more severe than either the Acta2+/+ R258C TG
or Acta2+/- SMCs due to the presence of increased mutant to wildtype α-actin in these cells.
This conclusion is also supported by the more severe phenotypes observed in vivo in these
mice (Fig. 1.8C).
The hypothesis that the R258C mutant actin forms brittle filaments is also supported
by preliminary in vitro data from the Trybus lab (Kathleen Trybus, PhD, and colleagues,
personal communication). An assessment of flexural rigidity of the wildtype and mutant αactin showed that the mutant was less flexible when compared to the wildtype, with a
tendency to break. Measuring the in vitro motility of the wildtype and mutant α-actin
revealed that myosin moved the R258C and R258H mutant actins significantly more slowly
compared to the wildtype (Kathleen Trybus, PhD, and colleagues, personal communication).
While experiments have not yet been conducted with mixed wild-type: mutant actin, as they
are found in vascular SMCs in individuals with heterozygous ACTA2 mutations and in our
mouse mutant SMCs, these preliminary data provide further support to our observations in
culture.
Our finding that the Acta2+/+

R258C TG

filaments break down more slowly than the

wildtype following treatment with Latrunculin A are also in agreement with the in vitro
findings by Dr. Trybus and colleagues (personal communication). First, the Acta2+/+ R258C TG
SMCs express significantly more α-actin compared to the wildtype SMCs and form more,
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but thinner, filaments as assessed by immunofluorescent staining. Therefore, the effects of
the Latrunculin A treatment might appear less striking in the Acta2+/+

R258C TG

SMCs

compared to the wildtype cells because there are more filaments depolymerizing
simultaneously. This is a plausible but probably only partial explanation since even after one
hour of treatment, the Acta2+/+ R258C TG SMCs still have intact filaments whereas the wildtype
SMCs have no filaments by 15 minutes. It is, therefore, likely that the Acta2+/+

R258C TG

filaments are also less dynamic compared to wildtype filaments. This conclusion is
supported by structural predictions that this mutation disrupts the opening and closing of the
ATP binding cleft (17). Actin depolymerization requires ATP breakdown into ADP+Pi,
followed by subsequent Pi release (35). Therefore, a defect in the ATP binding region,
which affects Pi release, could lead to slower depolymerization. Alternatively, it is possible
that Latrunculin A is not able to bind mutant actin and hence has only partial effect in the
Acta2+/+

R258C TG

SMCs. Further studies in vitro will be required to thoroughly assess the

filament dynamics of this mutant. Ultimately, our experiments suggest that the Acta2+/+ R258C
TG

SMC filaments do not dissociate more quickly than wildtype filaments in cultured SMCs,

but when force is applied to these cells as in the shearing step prior to F/G actin assays, the
filaments fall apart easily. It is tempting to speculate that the constant stretch and force on
the aortic wall in vivo has a similar effect on the filament integrity as does shearing in
culture. This hypothesis could potentially be tested by introducing hypertension, a common
risk factor for TAAD in humans, in the Acta2+/+ R258C TG mice, and thus increasing the force
exerted on the aortic wall. Assessment of the F/G actin ratios in the aortic SMCs may
demonstrate increased monomeric actin in the SMCs exposed to increased pressures.
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The differential localization of MRTF-A in the SMCs, along with the corresponding
changes in contractile gene expression and protein levels, provide a link between impaired
actin filament formation/stability and SMC phenotype. Acta2+/+

R258C TG

SMCs had

significantly more nuclear MRTF-A staining compared to the wildtype SMCs, and
corresponding increases in all contractile protein levels that were assessed. This confirms
our observation that the filaments in these SMCs are intact, and perhaps even more
numerous than in wildype cells, allowing MRTF-A localization in the nucleus. The Acta2+/R258C TG

SMCs, on the other hand, had significantly less MRTF-A in the nucleus than the

wildtype cells, which is in agreement with the observation that these SMCs have large pools
of monomeric actin, which sequesters MRTF-A in the cytoplasm. Surprisingly, these SMCs
had no difference in the gene expression levels of Acta2 and SM22α compared to the
wildtype cells, and increased expression of Cnn1 and Myh11, suggesting that constitutively
nuclear transcription co-factors like myocardin, may partially compensate for the
cytoplasmic sequestration of MRTF-A. Interestingly, the Acta2+/- SMCs did not show a
significant difference in the ratio of nuclear to cytoplasmic MRTF-A compared to the wildtype, but were significantly different from the Acta2+/-

R258C TG

SMCs. Further, the

heterozygous SMCs also did not show a difference in the expression of any contractile genes
compared to wildtype. Both Acta2+/-

R258C TG

and Acta2+/- SMCs, however, showed lower

protein expression levels than expected based on the gene expression data, suggesting that
they both may have increased protein turnover as well. This prediction could be tested by
performing a time-course assay with the translation inhibitor cycloheximide in order to
assess how quickly proteins are degraded after inhibition. Taken together, we have observed
three unique phenotypes in our three genotypes. The Acta2+/+ R258C TG mice form filaments
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and are highly differentiated based on MRTF-A nuclear localization and increased
contractile marker expression; the Acta2+/- SMCs form very few filaments and do not show
any changes in contractile gene expression and MRTF-A localization but have a decrease in
contractile markers at the protein level; finally, the Acta2+/- R258C TG SMCs have almost no
filament formation, decreased nuclear MRTF-A localization but partial increase in
contractile gene expression, coupled with a decrease in contractile protein levels.
Given the differential localization of MRTF-A in each cell line, we would have
predicted that the Acta2+/+ R258C TG and Acta2+/- R258C TG SMCs would have opposite rates of
proliferation. Interestingly, we found that both cell lines proliferated significantly more than
the wildtype SMCs. This finding is consistent with the established SRF: MRTF phenotype
switching axis for the Acta2+/-

R258C TG

SMCs – sequestering MRTF-A in the cytoplasm

allows SRF to bind other transcription factors that promote c-fos expression and cell growth.
While it is surprising that the Acta2+/+

R258C TG

SMCs did not show a decrease in

proliferation, these data are consistent with findings from the Acta2-/- SMCs, which also
showed a significant increase in contractile marker levels in conjunction with increased
proliferation (88). It has been shown previously that SMC precursor cells display this dual
phenotype during the early stages of vascular development (106). Further, reports have
suggested that deficits in contractile protein expression may not be required for growth and
proliferation to be initiated (107), and, conversely, that differentiation of SMCs in culture
also does not require a loss of proliferative activity (106; 108). Therefore, there is evidence
for an uncoupling of the two ends of the smooth muscle cell phenotypic spectrum, which
could help explain the unique phenotype we observed in the Acta2+/+ R258C TG and Acta2-/SMCs.
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With regard to the SRF: MRTF axis, the increased proliferation, in addition to
contractile gene expression, suggests that growth signals may be promoting proliferation
independently of SRF. Alternatively, SRF expression levels may be higher in these SMCs,
and so enough SRF is present to bind both types of transcriptional co-factors. Support for
the uncoupling between growth and differentiation via the SRF: MRTF axis was also found
in the dedifferentiated Myh11R247C/R247C SMCs (48). While RhoA activation restores
differentiation by inducing actin polymerization and driving MRTF-A back in the nucleus,
proliferation was not correspondingly attenuated by this process (48). Therefore, MRTF-A
translocation out of the nucleus can “sensitize” SMCs to proliferative stimuli, but
localization of MRTF-A in the nucleus does not prevent the SMCs from being sensitive to
other proliferation signals.
Mutations in contractile proteins identified in our lab have been shown to uniformly
decrease contractility and force generation in the aorta. As the demonstrated or hypothesized
decreased contractility is the underlying defect linking the mutations causing thoracic aortic
disease, we wanted to explore the link between the phenotypic changes and force generation.
We focused on focal adhesions, which are crucial signal transduction centers and integration
points for signaling and mechanical cues (39; 42). The composition of focal adhesions
depending on their maturity can drive additional cell processes and pathways that will affect
the cellular phenotype, and the progression of maturation of these focal adhesions is
dependent on increasing force generation across the cell driven by actin and myosin
filaments. For example, activators of RhoA are only found in mature focal adhesions (44);
RhoA regulates myosin light chain phosphorylation and actin stress fiber formation,
hallmarks of a differentiated cell. Activators of Rac1, on the other hand, are enriched in less
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mature FAs (44), and Rac1 is involved in proliferative and migratory signaling downstream
of growth factor receptors like the PDGFRβ (109), the angiotensin type 1 receptor (110),
and it may also be activated in response to reactive oxygen species (111).
We found in both the Acta2+/+

R258C TG

and Acta2+/-

R258C TG

SMCs that the focal

adhesions are fewer, more peripherally localized and larger compared with wildtype cells.
Further, these SMCs were enriched in activated FAK, suggested to play a role in focal
adhesion strengthening (112-113), in addition to focal adhesion turnover (114-115). These
findings are in line with the Acta2-/- SMC findings (88), providing further support to the
hypothesis that the disruptive effect of the R258C mutation induces a smooth muscle cell
phenotype similar to the one resulting from the complete loss of α-actin. Interestingly, the
Acta2+/+ R258C TG SMCs had a significant increase in the activation of Rac1 but no change in
RhoA activation, also in line with the Acta2-/- SMCs. However, the Acta2+/- R258C TG SMCs
and Acta2+/- SMCs showed a paradoxical decrease in Rac1, and the Acta2+/- R258C TG SMCs
had a slight but significant decrease in RhoA activation, which was unique to this cell line
and hence further supports an additive effect of the genetic alterations. This indicates that
there may be a decrease in total Rac1 and RhoA production or expression. The exact
mechanism, by which the loss of an α-actin allele could lead to a decrease in Rac1 and
RhoA activation, remains unclear, but probably stems directly from the altered focal
adhesion content. A summary of these findings if presented in Fig. 6.1.
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Figure 6.1: Model of the Effects of the Acta2 R258C Mutation in Acta2+/+ R258C TG and
Acta2+/- R258C TG SMCs
Our lab’s work is the first to address how mutations in contractile proteins affect the
focal adhesion phenotype. Thus, we are observing not only novel SMC phenotypes, but also
previously undescribed focal adhesion phenotypes. While work has been done to disrupt
actin polymerization or myosin II motor activity using specific inhibitors (43-44; 113), the
indirect effects of impaired contractile ability (coming from altered interactions with partner
molecules, for example) on focal adhesion maturation have not been addressed. Loss of
actin filament stability induces the formation of large focal adhesions, which are
traditionally considered to be more mature. However, the peripheral localization of these
adhesions (which suggests they are nascent), the activation of FAK, together with the
increase in Rac1 for the Acta2+/+ R258C TG SMCs and the decrease in RhoA in the Acta2+/-
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R258C TG

SMCs, indicate that the focal adhesions are not maturing properly. Thus, the dual

nature of the observed SMC phenotype is reflected in the focal adhesion phenotype, too.
We also wanted to test whether the proliferative pathways identified in the Acta2-/SMCs were similarly activated in the mutant cells. Our studies clearly indicate a role for
FAK in driving proliferation. While FAK inhibitor treatment had a modest effect on
attenuating proliferation in the Acta2+/+ R258C TG SMCs, it had a partial but significant effect
in the Acta2+/- R258C TG SMCs, which also had the greatest increase in activated FAK as seen
by Western blot. Together with the observation that Akt is not more activated in the SMCs
expressing more activated FAK, this data suggests that a key role for FAK in these SMCs is
in stimulating proliferative pathways.
In addition to assessing the contribution of FAK to proliferation in our SMCs, we
tested for growth factor receptor activation, focusing on the platelet-derived growth factor
receptor β (PDGFRβ). Expression of the receptor at the mRNA level was only marginally
significantly increased in the Acta2+/+ R258C TG SMCs. At the protein level, both the activated
receptor and total receptor protein levels were increased in these cells, which is in agreement
with findings in the Acta2-/- SMCs (88). Therefore, we tested whether imatinib could block
proliferation in our SMCs like it did for the null cells. The fact that imatinib reduced
proliferation to wildtype levels in the Acta2+/-

R258C TG

SMCs and only partially in the

Acta2+/+ R258C TG SMCs was surprising given the lack of increased activation in the PDGFRβ,
but it may possibly indicate a greater sensitivity of these SMCs to inhibitors of proliferation
like imatinib. Alternatively, imatinib, as a multi-target tyrosine kinase inhibitor, may be
affecting proliferation through any of its other main targets, such as Bcr/Abl and C-kit (116).
However, Bcr in SMCs is downstream of PDGF (117). C-kit, on the other hand, is more
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highly expressed in endothelial cells than SMCs (118), but its expression can increase in
VSMCs in response to injury (119). These data suggest that it is less likely that these
tyrosine kinases play a role in driving proliferation in culture. However, their increased
expression in response to injury (117; 119), together with the significant enrichment of c-kit
positive stem cells in the media of TAAD patients reported by Shen and colleagues (120),
suggests a role for multi-target tyrosine kinase inhibitors like imatinib in treating vascular
disease in patients with ACTA2 mutations.
One surprising finding from this study is the similarity in the cellular phenotypes of
the Acta2-/- SMCs and the Acta2+/+

R258C TG

SMCs. These SMCs have similar contractile

gene and protein expression, proliferation, MRTF-A localization, focal adhesion alterations
and response to imatinib treatment (88). The mouse models also display similar aortic
pathology, but the Acta2+/+

R258C TG

mouse pathology is predictably less severe than the

pathology of actin-deficient mice. Furthermore, wildtype SMCs treated with an α-actin
disrupting peptide also exhibit alterations in agreement with data presented here (88). These
findings suggest that the dominant negative effect of the R258C mutation, even with
wildtype α-actin present, can almost recapitulate the complete loss of the gene and gene
product in vitro. Furthermore, while the cellular phenotype that we characterized in the
Acta2+/- R258C TG SMCs was different from the ones in the Acta2+/+ R258C TG and Acta2-/- SMCs,
the Acta2+/- R258C TG mice develop more significant vascular pathology compared to the other
two genotypes. Taking the recurring findings in SMCs from the three models, it appears that
alterations or loss of α-actin drive the cellular and vascular phenotype in these mouse
models through impaired actin filament stability, focal adhesion rearrangements, FAK
activation, and increased proliferation. More work will be needed to detail the exact cause-
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and-effect sequence as a result of the mutant α-actin expression and to devise potential
treatments for the aortic disease in patients with ACTA2 R258C mutations.
In conclusion, the Acta2+/+

R258C TG

and Acta2+/-

R258C TG

mice are the first mouse

models of a recurring mutation that leads to FTAAD. The aortic phenotype in these mice
matches the observations in our patients, verifying that this is a good model of disease. We
sought to characterize the phenotype of vascular SMCs explanted from the ascending aorta
in order to gain better understanding of the cellular pathology associated with aneurysm
development, since little is known about the fate of SMCs in the early stages of disease
progression. The findings presented here, coupled with the ones from the Acta2-/- mouse
model, point towards a unique SMC phenotype resulting from a disruption or complete loss
of α-actin filaments, which is simultaneously proliferative and expressing contractile
markers (88). The similarity of results amongst our various models suggests that the
pathology noted in this study is most likely going to be replicated in SMCs from models of
other ACTA2 mutations. Further, and also importantly, the shared findings between the
Acta2-/- and Acta2+/+ R258C TG SMCs and mice imply that any treatments evaluated for aortic
or vascular occlusive disease may potentially be applicable to patients with other mutations
in ACTA2.
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APPENDIX
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Appendix 1: Characterization of the Acta2+/+ R258C TG2 SMCs. A. Acta2+/+ R258C TG2 SMCs
express Cnn1 and SM22α at significantly greater levels compared to wildtype cells, and
Acta2 and Myh11 and comparable levels. *p<0.05, **p<0.01. Error bars ± s.d. B. Increased
contractile protein expression in Acta2+/+ R258C TG2 SMCs. C. While Pdgfrb expression is not
increased, cfos is significantly more highly expressed in Acta2+/+ R258C TG2 SMCs, and the
PDGFRβ is more activated at the protein level when SMCs are grown on plastic, collagen
IV and fibronectin 1 alike. D. Proliferation is borderline significantly increased in Acta2+/+
R258C TG2
SMCs.
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Appendix 2: Immunofluorescent Staining of Wildtype and Acta2+/+ R258C TG2 SMCs. SM
α-actin = green, vinculin = green, phalloidin (total filamentous actin) = red, nucleus (DAPI)
= blue.
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Appendix 3: Quantification of Western Blots.

97

Bibliography

1. Castellano, J. M., Kovacic, J. C., Sanz, J., and Fuster, V. (2012). Are we ignoring the
dilated thoracic aorta? Ann NY Acad Sci 1254, 164-174.
2. IRAD Online.International Registry of Acute Aortic Dissection.
<http://www.iradonline.org/index.html>
3. LeMaire, S. A., and Russell, L. (2011). Epidemiology of thoracic aortic dissection. Nat
Rev Cardiol 8, 103-113.
4. Milewicz, D. M. (2011). Stopping a Killer: Improving the diagnosis, treatment, and
prevention of acute ascending aortic dissections Circulation 124, 1902-1904.
5. Milewicz, D. M., and Regalado, E.(February 13, 2003,updated January 12, 2012).In
GeneReviews (Pagon, R. A., Bird, T. D., and Dolan, C. R., eds), University of
Washington, Seattle, WA, 19936. Milewicz, D. M., Guo, D. C., Tran-Fadulu, V., Lafont, A. L., Papke, C. L., Inamoto, S.,
Kwartler, C. S., and Pannu, H. (2008). Genetic basis of thoracic aortic aneurysms
and dissections: focus on smooth muscle cell contractile dysfunction. Annu Rev
Genomics Hum Genet 9, 283-302.
7. Elefteriades, J. A. (2008). Thoracic Aortic Aneurysm: Reading the enemy's playbook.
Yale Journal of Biology and Medicine 81, 175-186.
8. El-Hamamsy, I., and Yacoub, M. H. (2009). Cellular and molecular mechanisms of
thoracic aortic aneurysms. Nat Rev Cardiol 6, 771-786.
9. Milewicz, D. M., Kwartler, C. S., Papke, C. L., Regalado, E. S., Cao, J., and Reid, A. J.
(2010). Genetic variants promoting smooth muscle cell proliferation can result in

98

diffuse and diverse vascular diseases: evidence for a hyperplastic vasculomyopathy.
Genet Med 12, 196-203.
10. Wolinsky, H., and Glagov, S. (1967). A lamellar unit of aortic medial structure and
function in mammals Circ Res 20, 99-111.
11. Bunton, T. E., Biery, N. J., Myers, L., Gayraud, B., Ramirez, F., and Dietz, H. C. (2001).
Phenotypic alteration of vascular smooth muscle cells precedes elastolysis in a
mouse model of Marfan Syndrome Circ Res 88, 37-43.
12. Zhang, X., Shen, Y. H., and LeMaire, S. A. (2009). Thoracic aortic dissection: are
matrix metalloproteinases involved? Vascular 17, 147-157.
13. Lowy, J., and Small, J. V. (1970). The organization of myosin and actin in vertebrate
smooth muscle. Nature 227, 46-51.
14. Owens, G. K., Kumar, M. S., and Wamhoff, B. R. (2004). Molecular regulation of
vascular smooth muscle cell differentiation in development and disease. Physiol Rev
84, 767-801.
15. McDonald, O. G., and Owens, G. K. (2007). Programming smooth muscle plasticity
with chromatin dynamics. Circ Res 100, 1428-1441.
16. Yoshida, T., Kaestner, K. H., and Owens, G. K. (2008). Conditional deletion of Krüppellike factor 4 delays downregulation of smooth muscle cell differentiation markers but
accelerates neointimal formation following vascular injury. Circ Res 102, 15481557.
17. Guo, D. C., Papke, C. L., Tran-Fadulu, V., Regalado, E. S., Avidan, N., Johnson, R. J.,
Kim, D. H., Pannu, H., Willing, M. C., Sparks, E., Pyeritz, R. E., Singh, M. N.,
Dalman, R. L., Grotta, J. C., Marian, A. J., Boerwinkle, E. A., Frazier, L. Q.,

99

LeMaire, S. A., Coselli, J. S., Estrera, A. L., Safi, H. J., Veeraraghavan, S., Muzny,
D. M., Wheeler, D. A., Willerson, J. T., Yu, R. K., Shete, S. S., Scherer, S. E.,
Raman, C. S., Buja, L. M., and Milewicz, D. M. (2009). Mutations in Smooth
Muscle Alpha-Actin (ACTA2) Cause Coronary Artery Disease, Stroke, and
Moyamoya Disease, Along with Thoracic Aortic Disease The American Journal of
Human Genetics 84, 617-627.
18. Kumar, M. S., and Owens, G. K. (2003). Combinatorial control of smooth musclespecific gene expression. Arterioscler Thromb Vasc Biol 23, 737-747.
19. Parmacek, M. S. (2007). Myocardin-Related Transcription Factors: Critical Coactivators
Regulating Cardiovascular Development and Adaptation Circ Res 100, 633-644.
20. Miano, J. M., Long, X., and Fujiwara, K. (2007). Serum response factor: master
regulator of the actin cytoskeleton and contractile apparatus. Am J Physiol Cell
Physiol 292, C70-C81.
21. Cen, B., Selvaraj, A., and Prywes, R. (2004). Myocardin/MKL family of SRF
coactivators: key regulators of immediate early and muscle specific gene expression.
J Cell Biochem 93, 74-82.
22. Hoofnagle, M. H., Neppl, R. L., Berzin, E. L., Teg Pipes, G. C., Olson, E. N., Wamhoff,
B. W., Somlyo, A. V., and Owens, G. K. (2011). Myocardin is differentially required
for the development of smooth muscle cells and cardiomyocytes. Am J Physiol Heart
Circ Physiol 300, H1707-H1721.
23. Oh, J., Richardson, J. A., and Olson, E. N. (2005). Requirement of myocardin-related
transcription factor-B for remodeling of branchial arch arteries and smooth muscle
differentiation PNAS 102, 15122-15127.

100

24. Hinson, J. S., Medlin, M. D., Lockman, K., Taylor, J. M., and Mack, C. P. (2007).
Smooth muscle cell-specific transcription is regulated by nuclear localization of the
myocardin-related transcription factors. Am J Physiol Heart Circ Physiol 292,
H1170-H1180.
25. Li, S., Chang, S., Qi, X., Richardson, J. A., and Olson, E. N. (2006). Requirement of a
myocardin-related transcription factor for development of mammary myoepithelial
cells. Mol Cell Biol 26, 5797-5808.
26. Nakamura, S., Hayashi, K., Iwasaki, K., Fujioka, T., Egusa, H., Yatani, H., and Sobue,
K. (2010). Nuclear import mechanism for myocardin family members and their
correlation with vascular smooth muscle cell phenotype. J Biol Chem 285, 3731437323.
27. Zhou, J., Hu, G., and Herring, B. P. (2005). Smooth muscle-specific genes are
differentially sensitive to inhibition by Elk-1. Mol Cell Biol 25, 9874-9885.
28. Mack, C. P., Somlyo, A. V., Hautmann, M., Somlyo, A. P., and Owens, G. K. (2001).
Smooth muscle differentiation marker gene expression is regulated by RhoAmediated actin polymerization The Journal of Biological Chemistry 276, 341-347.
29. Asparuhova, M. B., Gelman, L., and Chiquet, M. (2009). Role of the actin cytoskeleton
in tuning cellular responses to external mechanical stress Scandinavian Journal of
Medicine and Science in Sports 19, 490-499.
30. Guettler, S., Vartiainen, M. K., Miralles, F., Larijani, B., and Treisman, R. (2008).RPEL
motifs link the serum response factor cofactor MAL but not myocardin to Rho
signaling via actin binding. Mol Cell Biol 28, 732-742.

101

31. Yin, H., Jiang, Y., Li, H., Li, J., Gui, Y., and Zheng, X. L. (2011).Proteasomal
degradation of myocardin is required for its transcriptional activity in vascular
smooth muscle cells. J Cell Physiol 226, 1897-1906.
32. Kim, H. R., Gallant, C., Leavis, P. C., Gunst, S. J., and Morgan, K. G. (2008).
Cytoskeletal remodeling in differentiated vascular smooth muscle is actin isoform
dependent and stimulus dependent. Am J Physiol Cell Physiol 295, C768-C778.
33. Gabbiani, G., Schmid, E., Winter, S., Chaponnier, C., de Chastonay, C.,
Vandekerckhove, J., Weber, K., and Franke, W. W. (1981). Vascular smooth muscle
cells differ from other smooth muscle cells: predominance of vimentin filaments and
a specific alpha-type actin PNAS 78, 298-302.
34. Lim, S. M., Trzeciakowski, J. P., Sreenivasappa, H., Dangott, L. J., and Trache, A.
(2012). RhoA-induced cytoskeletal tension controls adaptive cellular remodeling to
mechanical signaling. Integr Biol (Camb)
35. Korn, E. D., Carlier, M. F., and Pantaloni, D. (1987). Actin polymerization and ATP
hydrolysis Science 238, 638-644.
36. Kueh, H. Y., Brieher, W. M., and Mitchison, T. J. (2008). Dynamic stabilization of actin
filaments PNAS 105, 16531-16536.
37. Dominguez, R., and Holmes, K. C. (2011). Actin structure and function. Annu Rev
Biophys 40, 169-186.
38. Chrzanowska-Wodnicka, M., and Burridge, K. (1996). Rho-stimulated contractility
drives the formation of stress fibers and focal adhesions. J Cell Biol 133, 1403-1415.
39. Huveneers, S., and Danen, E. H. (2009). Adhesion signaling - crosstalk between
integrins, Src and Rho. J Cell Sci 122, 1059-1069.

102

40. Lim, S. M., Kreipe, B. A., Trzeciakowski, J., Dangott, L., and Trache, A. (2010).
Extracellular matrix effect on RhoA signaling modulation in vascular smooth muscle
cells. Exp Cell Res 316, 2833-2848.
41. Godin, C. M., and Ferguson, S. S. (2010). The angiotensin II type 1 receptor induces
membrane blebbing by coupling to Rho A, Rho kinase, and myosin light chain
kinase. Mol Pharmacol 77, 903-911.
42. Provenzano, P. P., and Keely, P. J. (2011). Mechanical signaling through the
cytoskeleton regulates cell proliferation by coordinated focal adhesion and Rho
GTPase signaling. J Cell Sci 124, 1195-1205.
43. Choi, C. K., Vicente-Manzanares, M., Zareno, J., Whitmore, L. A., Mogilner, A., and
Horwitz, A. R. (2008). Actin and alpha-actinin orchestrate the assembly and
maturation of nascent adhesions in a myosin II motor-independent manner. Nat Cell
Biol 10, 1039-1050.
44. Kuo, J., Han, X., Hsiao, C., Yates, J. R., and Waterman, C. M. (2011). Analysis of the
myosin-II-responsive focal adhesion proteome reveals a role for βPix in negative
regulation of focal adhesion maturation Nature Cell Biology 13, 383-383.
45. Hinz, B. (2006). Masters and servants of the force: the role of matrix adhesions in
myofibroblast force perception and transmission. Eur J Cell Biol 85, 175-181.
46. Liu, B., Itoh, H., Louie, O., Kubota, K., and Kent, K. C. (2002). The signaling protein
Rho is necessary for vascular smooth muscle migration and survival but not for
proliferation. Surgery 132, 317-325.
47. Mack, C. P. (2011). Signaling mechanisms that regulate smooth muscle cell
differentiation. Arterioscler Thromb Vasc Biol 31, 1495-1505.

103

48. Kuang, S. Q., Kwartler, C. S., Byanova, K. L., Pham, J., Gong, L., Prakash, S. K.,
Huang, J., Kamm, K. E., Stull, J. T., Sweeney, H. L., and Milewicz, D. M. (2012).
Rare, Nonsynonymous Variant in the Smooth Muscle-Specific Isoform of Myosin
Heavy Chain, MYH11, R247C, Alters Force Generation in the Aorta and Phenotype
of Smooth Muscle Cells. Circ Res 110 (11), 1411-22.
49. Majesky, M. W. (2007). Developmental basis of vascular smooth muscle diversity.
Arterioscler Thromb Vasc Biol 27, 1248-1258.
50. Gadson, P. F., Dalton, M. L., Patterson, E., Svoboda, D. D., Hutchinson, L., Schram, D.,
and Rosenquist, T. H. (1997). Differential Response of Mesoderm- and Neural CrestDerived Smooth Muscle to TGF-β1: Regulation of c-myb and α1 (I) Procollagen
Genes. Experimental Cell Research 230, 169-180.
51. Topouzis, S., and Majesky, M. W. (1996). Smooth Muscle Lineage Diversity in the
Chick Embryo: Two Types of Aortic Smooth Muscle Cell Differ in Growth and
Receptor-Mediated Transcriptional Responses to Transforming Growth Factor-β.
Developmental Biology 178, 430-445.
52. Elefteriades, J. A., and Farkas, E. A. (2010). Thoracic aortic aneurysm: clinically
pertinent controversies and uncertainties. J Am Coll Cardiol 55, 841-857.
53. Brooke, B. S., Habashi, J. P., Judge, D. P., Patel, N., Loeys, B., and Dietz, H. C. (2008).
Angiotensin II Blockade and Aortic-Root Dilation in Marfan's Syndrome. The New
England Journal of Medicine 358, 2787-2795.
54. National Marfan Foundation. Marfan Syndrome. 2012.<www.marfan.org/marfan>
55. Habashi, J. P., Judge, D. P., Holm, T. M., Cohn, R. D., Loeys, B. L., Cooper, T. K.,
Myers, L., Klein, E. C., Liu, G., Calvi, C., Podowski, M., Neptune, E. R., Halushka,

104

M. K., Bedja, D., Gabrielson, K., Rifkin, D. B., Carta, L., Ramirez, F., Huso, D. L.,
and Dietz, H. C. (2006). Losartan, an AT1 antagonist, prevents aortic aneurysm in a
mouse model of Marfan syndrome. Science 312, 117-121.
56. McLoughlin, D., McGuinness, J., Byrne, J., Terzo, E., Huuskonen, V., McAllister, H.,
Black, A., Kearney, S., Kay, E., Hill, A. D., Dietz, H. C., and Redmond, J. M.
(2011). Pravastatin reduces Marfan aortic dilation. Circulation 124, S168-S173.
57. Loeys, B. L., Schwarze, U., Holm, T., Callewaert, B. L., Thomas, G. H., Pannu, H., De
Backer, J. F., Oswald, G. L., Symoens, S., Manouvrier, S., Roberts, A. E., Faravelli,
F., Greco, M. A., Pyeritz, R. E., Milewicz, D. M., Coucke, P. J., Cameron, D. E.,
Braverman, A. C., Byers, P. H., De Paepe, A. M., and Dietz, H. C. (2006). Aneurysm
Syndromes Caused by Mutations in the TGF-beta Receptor The New England
Journal of Medicine 355, 788-798.
58. Loeys-Dietz Syndrome Foundation.Loeys-Dietz Syndrome.2008.<http://loeysdietz.org>
59. Kalra, V. B., Gilbert, J. W., and Malhotra, A. (2011). Loeys-Dietz syndrome:
cardiovascular, neuroradiological and musculoskeletal imaging findings. Pediatr
Radiol 41, 1495-504; quiz 1616.
60. Ong, K. T., Perdu, J., De Backer, J., Bozec, E., Collignon, P., Emmerich, J., Fauret, A.
L., Fiessinger, J. N., Germain, D. P., Georgesco, G., Hulot, J. S., De Paepe, A.,
Plauchu, H., Jeunemaitre, X., Laurent, S., and Boutouyrie, P. (2010). Effect of
celiprolol on prevention of cardiovascular events in vascular Ehlers-Danlos
syndrome: a prospective randomised, open, blinded-endpoints trial. Lancet 376,
1476-1484.

105

61. Prakash, S. K., LeMaire, S. A., Guo, D. C., Russell, L., Regalado, E. S., Golabbakhsh,
H., Johnson, R. J., Safi, H. J., Estrera, A. L., Coselli, J. S., Bray, M. S., Leal, S. M.,
Milewicz, D. M., and Belmont, J. W. (2010). Rare copy number variants disrupt
genes regulating vascular smooth muscle cell adhesion and contractility in sporadic
thoracic aortic aneurysms and dissections. Am J Hum Genet 87, 743-756.
62. Kuang, S. Q., Guo, D. C., Prakash, S. K., McDonald, M. L., Johnson, R. J., Wang, M.,
Regalado, E. S., Russell, L., Cao, J. M., Kwartler, C., Fraivillig, K., Coselli, J. S.,
Safi, H. J., Estrera, A. L., Leal, S. M., Lemaire, S. A., Belmont, J. W., Milewicz, D.
M., and GenTAC Investigators (2011). Recurrent chromosome 16p13.1 duplications
are a risk factor for aortic dissections. PLoS Genet 7, e1002118.
63. LeMaire, S. A., McDonald, M. L., Guo, D. C., Russell, L., Miller, C. C., Johnson, R. J.,
Bekheirnia, M. R., Franco, L. M., Nguyen, M., Pyeritz, R. E., Bavaria, J. E.,
Devereux, R., Maslen, C., Holmes, K. W., Eagle, K., Body, S. C., Seidman, C.,
Seidman, J. G., Isselbacher, E. M., Bray, M., Coselli, J. S., Estrera, A. L., Safi, H. J.,
Belmont, J. W., Leal, S. M., and Milewicz, D. M. (2011). Genome-wide association
study identifies a susceptibility locus for thoracic aortic aneurysms and aortic
dissections spanning FBN1 at 15q21.1. Nat Genet 43, 996-1000.
64. Inamoto, S., Kwartler, C. S., Lafont, A. L., Liang, Y. Y., Fadulu, V. T., Duraisamy, S.,
Willing, M., Estrera, A., Safi, H., Hannibal, M. C., Carey, J., Wiktorowicz, J., Tan,
F. K., Feng, X. H., Pannu, H., and Milewicz, D. M. (2010). TGFBR2 mutations alter
smooth muscle cell phenotype and predispose to thoracic aortic aneurysms and
dissections. Cardiovasc Res 88, 520-529.

106

65. Regalado, E. S., Guo, D. C., Villamizar, C., Avidan, N., Gilchrist, D., McGillivray, B.,
Clarke, L., Bernier, F., Santos-Cortez, R. L., Leal, S. M., Bertoli-Avella, A. M.,
Shendure, J., Rieder, M. J., Nickerson, D. A., NHLBI GO Exome Sequencing
Project, and Milewicz, D. M. (2011). Exome sequencing identifies SMAD3
mutations as a cause of familial thoracic aortic aneurysm and dissection with
intracranial and other arterial aneurysms. Circ Res 109, 680-686.
66. Wang, L., Guo, D. C., Cao, J., Gong, L., Kamm, K. E., Regalado, E., Li, L., Shete, S.,
He, W. Q., Zhu, M. S., Offermanns, S., Gilchrist, D., Elefteriades, J., Stull, J. T., and
Milewicz, D. M. (2010). Mutations in myosin light chain kinase cause familial aortic
dissections. Am J Hum Genet 87, 701-707.
67. Zhu, L., Vranckx, R., Khau Van Kien, P., Lalande, A., Boisset, N., Mathieu, F.,
Wegman, M., Glancy, L., Gasc, J. M., Brunotte, F., Bruneval, P., Wolf, J. E., Michel,
J. B., and Jeunemaitre, X. (2006). Mutations in myosin heavy chain 11 cause a
syndrome associating thoracic aortic aneurysm/aortic dissection and patent ductus
arteriosus. Nat Genet 38, 343-349.
68. Pannu, H., Tran-Fadulu, V., Papke, C. L., Scherer, S., Liu, Y., Presley, C., Guo, D.,
Estrera, A. L., Safi, H. J., Brasier, A. R., Vick, G. W., Marian, A. J., Raman, C. S.,
Buja, L. M., and Milewicz, D. M. (2007). MYH11 mutations result in a distinct
vascular pathology driven by insulin-like growth factor 1 and angiotensin II. Hum
Mol Genet 16, 2453-2462.
69. Renard, M., Callewaert, B., Baetens, M., Campens, L., Macdermot, K., Fryns, J. P.,
Bonduelle, M., Dietz, H. C., Gaspar, I. M., Cavaco, D., Stattin, E. L., SchranderStumpel, C., Coucke, P., Loeys, B., De Paepe, A., and De Backer, J. (2011). Novel

107

MYH11 and ACTA2 mutations reveal a role for enhanced TGFβ signaling in
FTAAD. Int J Cardiol
70. Guo, D. C., Pannu, H., Tran-Fadulu, V., Papke, C. L., Yu, R. K., Avidan, N., Bourgeois,
S., Estrera, A. L., Safi, H. J., Sparks, E., Amor, D., Ades, L., McConnell, V.,
Willoughby, C. E., Abuelo, D., Willing, M., Lewis, R. A., Kim, D. H., Scherer, S.,
Tung, P. P., Ahn, C., Buja, L. M., Raman, C. S., Shete, S. S., and Milewicz, D. M.
(2007). Mutations in smooth muscle alpha-actin (ACTA2) lead to thoracic aortic
aneurysms and dissections. Nat Genet 39, 1488-1493.
71. Morisaki, H. (2009). Mutation of ACTA2 gene as an important cause of familial and
nonfamilial nonsyndromatic thoracic aortic aneurysm and/or dissection (TAAD)
Human Mutation 30, 1406-1411.
72. Milewicz, D. M., Østergaard, J. R., Ala-Kokko, L. M., Khan, N., Grange, D. K.,
Mendoza-Londono, R., Bradley, T. J., Olney, A. H., Adès, L., Maher, J. F., Guo, D.,
Buja, L. M., Kim, D., Hyland, J. C., and Regalado, E. S. (2010). De novo ACTA2
mutation causes a novel syndrome of multisystemic smooth muscle dysfunction. Am
J Med Genet A 152A, 2437-2443.
73. Yoo, E. H., Choi, S. H., Jang, S. Y., Suh, Y. L., Lee, I., Song, J. K., Choe, Y. H., Kim, J.
W., Ki, C. S., and Kim, D. K. (2010). Clinical, pathological and genetic analysis of a
Korean familiy with thoracic aortic aneurysms and dissections carrying a novel
Asp26Tyr mutation Annals of Clinical and Laboratory Science 40
74. Disabella, E., Grasso, M., Gambarin, F. I., Narula, N., Dore, R., Favalli, V., Serio, A.,
Antoniazzi, E., Mosconi, M., Pasotti, M., Odero, A., and Arbustini, E. (2011). Risk

108

of dissection in thoracic aortic aneurysms associated with mutations of smooth
muscle alpha-actin 2 (ACTA2) Heart 97, 321-326.
75. Hoffjan, S., Waldmüller, S., Blankenfeldt, W., Kötting, J., Gehle, P., Binner, P., Epplen,
J. T., and Scheffold, T. (2011). Three novel mutations in the ACTA2 gene in
German patients with thoracic aortic aneurysms and dissections. Eur J Hum Genet
19, 520-524.
76. Imai, T., Horigome, H., Shiono, J., and Hiramatsu, Y. (2011). Isolated giant ascending
aortic aneurysm in a child- a novel mutation of the ACTA2 gene European Journal
of Cardio-thoracic Surgery 40, e156-e157.
77. Mundia, M. M., Demers, R. W., Chow, M. L., Perieteanu, A. A., and Dawson, J. F.
(2012). Subdomain location of mutations in cardiac actin correlate with type of
functional change. PLoS One 7, e36821.
78. Bergeron, S. E., Wedemeyer, E. W., Lee, R., Wen, K. K., McKane, M., Pierick, A. R.,
Berger, A. P., Rubenstein, P. A., and Bartlett, H. L. (2011). Allele-specific effects of
thoracic aortic aneurysm and dissection alpha-smooth muscle actin mutations on
actin function. J Biol Chem 286, 11356-11369.
79. Cao, J., and Villamizar, C. Lab of Dianna Milewicz, MD, PhD, University of Texas
Health Science Center in Houston, TX. Unpublished work.
80. Chang, A., Kamm, K. E., and Stull, J. Lab of James Stull, PhD and Kristine E. Kamm,
PhD. University of Texas Southwestern Medical Center, Dallas, TX. Unpublished
work.
81. Villamizar, C. Lab of Dianna Milewicz, MD, PhD, University of Texas Health Science
Center in Houston, TX. Unpublished work.

109

82. Huang, J., Kamm, K. E., and Stull, J.Lab of James Stull, PhD and Kristine E. Kamm,
PhD. University of Texas Southwestern Medical Center, Dallas, TX. Unpublished
work.
83. Kumar, A. and Lindner, V. (1997). Remodeling with neointima formation in the mouse
carotid artery after cessation of blood flow. Arterioscler Thromb Vasc Biol 17, 22382244.
84. Schildmeyer, L. A., Braun, R., Taffet, G., Debiasi, M., Burns, A. E., Bradley, A., and
Schwartz, R. J. (2000). Impaired vascular contractility and blood pressure
homeostasis in the smooth muscle alpha-actin null mouse. FASEB J 14, 2213-2220.
85. Haaksma, C. J., Schwartz, R. J., and Tomasek, J. J. (2011). Myoepithelial Cell
Contraction and Milk Ejection Are Impaired in Mammary Glands of Mice Lacking
Smooth Muscle Alpha-Actin Biology of Reproduction 85, 13-21.
86. Weymouth, N., Shi, Z., and Rockey, D. C. (2012). Smooth muscle α actin is specifically
required for the maintenance of lactation. Dev Biol 363, 1-14.
87. Papke, C. L., Cao, J., and Villamizar, C. Lab of Dianna Milewicz, MD, PhD, University
of Texas Health Science Center in Houston, TX. Unpublished work.
88. Papke, C. L., Cao, J., Kwartler, C. S., Villamizar, C., Byanova, K. L., Lim, S., Wang,
M., Rees, M., Chaponnier, C., Gabbiani, G., Khakoo, A. Y., Chandra, J., Trache, A.,
Zimmer, W., and Milewicz, D. M. Loss of Smooth Muscle α-actin Increases Smooth
Muscle Cell Proliferation Through Altered Focal Adhesions and Ligand-Independent
Platelet Derived Growth Factor Receptor-β Activation. Unpublished manuscript.
89. Tang, Y., Urs, S., Boucher, J., Bernaiche, T., Venkatesh, D., Spicer, D. B., Vary, C. P.,
and Liaw, L. (2010). Notch and transforming growth factor-beta (TGFbeta) signaling

110

pathways cooperatively regulate vascular smooth muscle cell differentiation. J Biol
Chem 285, 17556-17563.
90. Schlaepfer, D. D., Hanks, S. K., Hunter, T., and van der Geer, P. (1994). Integrinmediated signal transduction linked to Ras pathway by GRB2 binding to focal
adhesion kinase Nature 372, 786-791.
91. Schlaepfer, D. D., and Hunter, T. (1996). Signal transduction from the extracellular
matrix - a role for the focal adhesion protein-tyrosine kinase FAK. Cell Structure
and Function 21, 445-450.
92. Wang, D., Grammer, J. R., Cobbs, C. S., Stewart, J. E., Liu, Z., Rhoden, R., Hecker, T.
P., Ding, Q., and Gladson, C. L. (2000). p125 focal adhesion kinase promotes
malignant astrocytoma cell proliferation in vivo Journal of Cell Science 113, 42214230.
93. Chaturvedi, L. S., Marsh, H. M., and Basson, M. D. (2007). Src and focal adhesion
kinase mediate mechanical strain-induced proliferation and ERK1/2 phosphorylation
in human H441 pulmonary epithelial cells. Am J Physiol Cell Physiol 292, C1701C1713.
94. Schneller, M., Vuori, K., and Ruoslahti, E. (1997). αvβ3 integrin associates with
activated insulin and PDGFβ receptors and potentiates the biological activity of
PDGF. EMBO J 16, 5600-5607.
95. Woodard, A. S., García-Cardeña, G., Leong, M., Madri, J. A., Sessa, W. C., and
Languino, L. R. (1998). The synergistic activity of αvβ3 integrin and PDGF receptor
increases cell migration. J Cell Sci 111 (4), 469-478.

111

96. Eliceiri, B. P. (2001). Integrin and Growth Factor Receptor Crosstalk Circ Res 89, 11041110.
97. Schwartz, S. M. (1997). Smooth muscle migration in vascular development and
pathogenesis. Transplant Immunology 5, 255-260.
98. Myllärniemi, M., Calderon, L., Lemström, K., Buchdunger, E., and Häyry, P. (1997).
Inhibition of platelet-derived growth factor receptor tyrosine kinase inhibits vascular
smooth muscle cell migration and proliferation. FASEB J 11, 1119-1126.
99. Pichon, S., Bryckaert, M., and Berrou, E. (2004). Control of actin dynamics by p38
MAP kinase - Hsp27 distribution in the lamellipodium of smooth muscle cells. J Cell
Sci 117, 2569-2577.
100.National

Cancer

Institute.

Cancer

Drug

Information

-

Imatinib

Mesylate.<http://www.cancer.gov/cancertopics/druginfo/imatinibmesylate>
101. Ghofrani, H. A., Seeger, W., and Grimminger, F. (2005). Imatinib for the treatment of
pulmonary arterial hypertension. The New England Journal of Medicine 353
102. ten Freyhaus, H., Dumitrescu, D., Berghausen, E., Vantler, M., Caglayan, E., and
Rosenkranz, S. (2012). Imatinib mesylate for the treatment of pulmonary arterial
hypertension. Expert Opin Investig Drugs 21, 119-134.
103. Lasater, E. A., Bessler, W. K., Mead, L. E., Horn, W. E., Clapp, D. W., Conway, S. J.,
Ingram, D. A., and Li, F. (2008). Nf1+/- mice have increased neointima formation via
hyperactivation of a Gleevec-sensitive molecular pathway. Hum Mol Genet 17,
2336-2344.

112

104. Wendel, H., and Dancker, P. (1987). Influence of phalloidin on both the nucleation and
the elongation phase of actin polymerization. Biochimica et Biophysica Acta 915,
199-204.
105. Trybus, K. M., Fagnant, Patty and Sckolnick, Maria. 2012. Personal communication.
106. Lee, S. H., Hungerford, J. E., Little, C. D., and Iruela-Arispe, M. L. (1997).
Proliferation and differentiation of smooth muscle cell precursors occurs
simultaneously during the development of the vessel wall. Dev Dyn 209, 342-352.
107. Owens, G. K., Loeb, A., Gordon, D., and Thompson, M. M. (1986).Expression of
smooth muscle-specific alpha-isoactin in cultured vascular smooth muscle cells:
relationship between growth and cytodifferentiation. J Cell Biol 102, 343-352.
108. De Mey, J. G., Uitendaal, M. P., Boonen, H. C., Vrijdag, M. J., Daemen, M. J., and
Struyker-Boudier, H. A. (1989). Acute and long-term effects of tissue culture on
contractile reactivity in renal arteries of the rat. Circ Res 65, 1125-1135.
109. Hawkins, P. T., Eguinoa, A., Qiu, R. G., Stokoe, D., Cooke, F. T., Walters, R.,
Wennström, S., Claesson-Welsh, L., Evans, T., and Symons, M. (1995). PDGF
stimulates an increase in GTP-Rac via activation of phosphoinositide 3-kinase. Curr
Biol 5, 393-403.
110. Higuchi, S., Ohtsu, H., Suzuki, H., Shirai, H., Frank, G. D., and Eguchi, S. (2007).
Angiotensin II signal transduction through the AT1 receptor: novel insights into
mechanisms and pathophysiology. Clin Sci (Lond) 112, 417-428.
111. Vecchione, C., Carnevale, D., Di Pardo, A., Gentile, M. T., Damato, A., Cocozza, G.,
Antenucci, G., Mascio, G., Bettarini, U., Landolfi, A., Iorio, L., Maffei, A., and
Lembo, G. (2009). Pressure-induced vascular oxidative stress is mediated through

113

activation of integrin-linked kinase 1/βPIX/Rac-1 pathway. Hypertension 54, 10281034.
112. Michael, K. E., Dumbauld, D. W., Burns, K. L., Hanks, S. K., and García, A. J. (2009).
Focal adhesion kinase modulates cell adhesion strengthening via integrin activation.
Mol Biol Cell 20, 2508-2519.
113. Dumbauld, D. W., Shin, H., Gallant, N. D., Michael, K. E., Radhakrishna, H., and
García, A. J. (2010). Contractility modulates cell adhesion strengthening through
focal adhesion kinase and assembly of vinculin-containing focal adhesions. J Cell
Physiol 223, 746-756.
114. Ilic, D., Furuta, Y., Kanazawa, S., Takeda, N., Sobue, K., Nakatsuji, N., Nomura, S.,
Fujimoto, J., Okada, M., Yamamoto, T., and Aizawa, S. (1995). Reduced cell
motility and enhanced focal adhesion contact formation in cells from FAK-deficient
mice Nature 377, 539-544.
115. Webb, D. J., Donais, K., Whitmore, L. A., Thomas, S. M., Turner, C. E., Parsons, J. T.,
and Horwitz, A. F. (2004). FAK-Src signalling through paxillin, ERK and MLCK
regulates adhesion disassembly. Nat Cell Biol 6, 154-161.
116. Pardanani, A., and Tefferi, A. (2004). Imatinib targets other than bcr/abl and their
clinical relevance in myeloid disorders. Blood 104, 1931-1939.
117. Alexis, J. D., Wang, N., Che, W., Lerner-Marmarosh, N., Sahni, A., Korshunov, V. A.,
Zou, Y., Ding, B., Yan, C., Berk, B. C., and Abe, J. (2009). Bcr kinase activation by
angiotensin

II

inhibits

peroxisome-proliferator-activated

receptor

gamma

transcriptional activity in vascular smooth muscle cells. Circ Res 104, 69-78.

114

118. Liu, X., Cheng, Y., Yang, J., Xu, L., and Zhang, C. (2012). Cell-specific effects of
miR-221/222 in vessels: molecular mechanism and therapeutic application. J Mol
Cell Cardiol 52, 245-255.
119. Wang, C. H., Verma, S., Hsieh, I. C., Hung, A., Cheng, T. T., Wang, S. Y., Liu, Y. C.,
Stanford, W. L., Weisel, R. D., Li, R. K., and Cherng, W. J. (2007). Stem cell factor
attenuates vascular smooth muscle apoptosis and increases intimal hyperplasia after
vascular injury. Arterioscler Thromb Vasc Biol 27, 540-547.
120. Shen, Y. H., Hu, X., Zou, S., Wu, D., Coselli, J. S., and Lemaire, S. A. (2012). Stem
cells in thoracic aortic aneurysms and dissections: potential contributors to aortic
repair. Ann Thorac Surg 93, 1524-1533.

115

Vita
Katerina Lyubomirova Byanova was born in Sofia, Bulgaria on June 18, 1987 and is the
daughter of Donka Stoyanova Stoyanova and Lubomir Borissov Bianov. After successfully
completing the International Baccalaureate Program and graduating from Red Cross Nordic
United World College in Flekke, Norway in May 2005, she went on to attend Amherst
College in Amherst, MA, from which she earned the degree of Bachelor of Arts in Biology
cum laude in May 2009. Katerina enrolled at the University of Texas Graduate School of
Biomedical Sciences in August 2010. She will graduate with a Master of Science in June
2012.

Permanent address:
Dianabad, bl.11, entr. 2, ap. 40
Sofia 1172,
Bulgaria
Email: katerinabyanova@gmail.com

116

